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SCOPE OF THIS THESIS 
In the general introductory part of this thesis (Chapters and 2) a 
review of some pertinent literature related to sleep-waking states and opioid 
peptides is offered. A global view of the neurochemical mechanisms and 
theories of functions of sleep, as well as the physiological and possible 
clinical consequences of total or selective REM sleep deprivation is given in 
Chapter 1. In Chapter 2, which is concerned with the role of endogenous 
opioid peptides, particular attention is paid to the possible modulatory role 
of endogenously released opioid peptides in the regulation of some behavioural 
states in physiological and pathological conditions. 
It is generally known that exogenously administered opiates and opioid 
A possible peptides can alter sleep pattern and decrease REM sleep. 
interaction between sleep-waking states and endogenous opioid system is 
suggested by the report that the episodic release of plasma humoral endorphins 
during sleep is associated with the REM sleep phase (Chapter 1, section 
1.1 .7). In addition, the concentrations of opioid peptides in some brain 
nuclei of the rat which are known to be important in sleep-waking regulation, 
are highest in the dark (active) phase, during which wakefulness is high and 
lowest in the light (rest) phase, when the propensity to sleep is at its 
highest (Chapter section 1 .3.2). Thus in order to clarify the effect of 
endogenously released opioid peptides in the regulation of sleep-waking 
pattern, we studied the effects of phosphoramidon, an inhibitor of 
enkephalinase A on sleep-waking states (Chapter 3). Several clinical studies 
suggest that the sleep-waking cycle may modulate the occurence of some types 
of epileptic phenomena in human subjects (Chapter 1, section 1 .5.2, iii). In 
addition, some studies indicate a similarity between enkephalin induced 
epileptic 
Therefore, 
phenomena and 
we studied 
petit 
the 
mal epilepsy 
effects of 
(Chapter 4 discussion). 
different sleep stages on 
enkephalin-induced epileptic phenomena using electrophysiological parameters 
(Chapter 4). 
These initial studies (Chapters 3 and 4) suggested an interaction between 
sleep-waking states and endogenous opioid system. The observation that REM 
sleep deprivation (REMSD) reduced the pain threshold to noxious electrical 
stimulation (Chapter 1 section 1 .5.2d i) was an indication of the importance 
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of REM sleep in the regulation of nociception. Therefore in Chapters 5 and 6, 
the experiments were designed to explore a direct effect of REMSD on the 
analgesic effects of morphine, an enkephalinase inhibitor phosphoramdion and 
cold-water-swim. 
The profound antagonistic effect of REMSD on opiate/opioid peptide induced 
analgesia stimulated further interest to investigate the relationship between 
REMSD and other opiate/opioid peptide modulated behavioural phenomena. 
Therefore the following opioid modulated behaviours were investigated: 
akinetic-cataleptic syndrome, spontaneous vertical motor activity, 
convulsions, 
(Chapters 7-9). 
(Chapter 10) 
grooming, wet-dog-shakes and morphine withdrawal symptoms 
Additional experiments with nitrous oxide were performed 
since it is known that this anaesthetic agent can stimulate the 
release of endogenous enkephalins and induce opiate-like withdrawal symptoms 
(Chapter 2, section 2.5.2, iv). 
Finally, the possible clinical consequences of our findings are described 
in the relevant chapters. 
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PART I: GENERAL INTRODUCTION 
CHAPTER 1 
NEUROBIOLOGY OF SLEEP-WAKING STATES 
Sleep is a heterogenous process organised into rhythmically occurring 
cycles of different stages which are characterised by specific behavioural, 
electrophysiological, autonomic and endocrine changes. Broadly, sleep is 
divided into non-rapid-eye-movement (NREM) sleep and rapid-eye-movement (REM) 
sleep, also called paradoxical sleep (PS) (Aserinsky and Kleitman, 1953). 
REM sleep occupies a large part of neo-natal mammalian sleep (Roffwarg et 
al., 1966) suggesting an involvement of REM sleep in brain maturation (Corner 
et al. 1980). In adult mammals REM sleep appears to regulate adaptivity and 
plasticity of waking behaviour (McGrath and Cohen, 1978). 
1.1 Sleep-wakefulness phenomenology 
Sleep and wakefulness, like many life processes from heart-beating to 
bird migration and hibernation, follow a certain pattern of oscillations, 
which are regulated by a strict space-time system as well as body position. 
In nocturnal rodents such as rats, sleep occupies 80% of the light phase and 
20 %the dark period. REM sleep, which occupies 15-20% of the total sleep 
time in adult rats, shows a slight prepondrance during the light phase 
(Borbely, 1982). 
1.1.1 Behaviour 
Pre-sleep behavioural repertory is characterised by the searching for a 
safe niche and preparing the body (grooming) for sleep (Parmeggianni, 1980; 
Cooper, 1979). Behaviourally, sleep onset is characterised by the suspension 
of active contact with the environment (Parmeggianni, 1980). 
A close relationship between electrographic recordings and behaviour has 
been observed in most animals so far studied. However there is a growing 
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body of evidence that behaviour and the usual electrophysiological correlates 
may become dissociated (Sakai, 1985). 
1 .1.2 Motor functions 
Sleep-wakefulness cycle is accompanied by phasic changes in motor 
activity. In general, quiescience of motor and postural support is a basic 
feature of sleep. With the onset of sleep there is a progressive decrease in 
electromyogram (EMG). During NREM sleep muscle tonus is present in an 
attenuated form, whereas when the animal enters into REM sleep, there is 
complete loss of the antigravity muscle tonus with consequent failure of 
postural support (Ursin, 1968; Timo-Iaria et al., 1970). Other important 
phasic motoric phenomena associated with REM sleep include, myoclonic 
twitching and burst of rapid eye movements. 
1.1.3 Neuronal activity 
The pattern and intensity of neuronal activity in some brain areas is 
often related to the state of vigilance. Bioelectric rhythms of the 
neocortex, hippocampus, lateral geniculate body, reticular formation and 
other brain areas have been studied extensively during sleep-wakefulness 
cycle (Steriade et al., 1977). 
i) Neocortex 
The neocortical EEG patterns of the rat during different vigilance states 
has been well documented (Timo-Iaria et al. 1970; Terrier and Gottesman, 
1978). Based on these reports the EEG of sleep-wakefulness cycle of the rat 
can be differentiated into four distinct stages as follows:-
a) Wakefulness in rat is characterised by desynchronised (fast) waves (30 -40 Hz 
and 30 ~v amplitude). 
b) Light slow wave sleep (LSWS) in the rat consists of spindles (6-12 Hz range, 
20-40 msec. 50-300 ~V), K-complexes and some delta waves in frontal-parietal 
cortex EEG. 
c) Delta sleep: This stage of NREM sleep consists of predominantly delta waves 
(>50%). 
d) REM sleep in the rat is characterised by desynchronised (fast) waves (20 Hz, 
40 ~V) in the frontal-parietal cortex. 
In the cat sleep-wakefulness is differentiated into five stages as 
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follows: active and quiet wakefulness, light slow sleep, deep slow wave 
sleep and REM sleep (Ursin, 1968). 
ii) Hippocampus and entorhinal cortex 
The electrical activity of the hippocampus and the entorhinal cortex 
undergo distinct oscillations which correlate well with specific vigilance 
states in the sleep-wakefulness continuum. During exploratory wakefulness 
and REM sleep, the dorsal hippocampal EEG show a regular theta wave pattern 
(4-6Hz) in both rats and cats (Jouvet et al., 1959; Monmaur et al., 1979). 
In NREM sleep the hippocampus and the entorhinal cortex present an irregular 
EEG pattern consisting of high amplitude sharp waves intermingled with slow 
waves (Jouvet et al .• 1959). In the ventral hippocampus spikes waves 
(100-300 #V, 50-100 msec duration) are most frequent during NREM sleep and 
are rare during wakefulness and REM sleep (Jouvet et al., 1959; Hartse et 
al.. 1979). 
iii) Reticular formation and lateral geniculate bo~ 
Phasic EEG spike activity during REM sleep was first demonstrated to 
occur in the cat pontine reticular formation by Jouvet and Michel (1959). 
lateral geniculate body by Mikiten and co-workers (1961) and in occipital 
(visual) cortex by Mouret and co-workers (1963). These spikes have been 
designated ponto-geniculo-occipital {PGO) waves according to the loci from 
which they were recorded. PGO waves have not been demonstrated in rats 
(Stern et al., 1974). They have not been unambiguously demonstrated in human 
subjects (Gaillard, 1980). The phasic PGO spike waves occur a few minutes 
prior and during REM episode and are generally absent during wakefulness and 
NREM sleep (Hartse et al., 1979). 
1.1.4 Respiration 
Cyclic changes in respiration have 
sleep-wakefulness cycle (Parmeggiani, 1980; 
been observed during the 
McGinty and Beahm, 1 984). 
During NREM sleep breathing is generally slower, shallow and more regular 
than in wakefulness. Only small changes in ventilatory response to carbon 
dioxide and mechanoceptive reflex occur during NREM sleep compared with 
wakefulness. In both experimental animals and human subjects, the 
respiratory rate is irregular, highly variable and may be accompanied by 
brief apneas during REM sleep. Arousal thresholds in response to hypoxia and 
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hypercapnia are increased during REM sleep compared vith NREM sleep. In 
addition, response to laryngeal stimulation during REM sleep could consist of 
apnea instead of the usual coughing. 
1 .1.5 Cardiovascular system 
The heart rate and arterial blood pressure are decreased in both man and 
animals during NREM sleep compared with wakefulness (Snyder et al., 1964). 
The largest drop in heart rate and systemic arterial blood pressure in cat 
was observed during REM sleep (Guazzi and Zanchetti, 1965). However in man 
heart rate and blood pressure are increased during REM sleep with respect to 
NREM sleep (Snyder et al., 1964). 
1.1.6 Thermoregulation 
An ultradian rhythm of homeostasis-poikilostasis which correlate with 
specific vigilance state has been documented (Parmeggiani, 1980; McGinty and 
Beahm, 1984). During NREM sleep, the core temperature is regulated at a 
lower set point compared with wakefulness. The decrease in body temperature 
is probably due to a combination of the thermoregulatory and passive 
processes such as reduction in motor action. In contrast to NREM sleep, 
hypothalamic thermoregulatory mechanisms are inactivated during REM sleep. 
Physiological and behavioural symptoms such as shivering, thermal 
vasodilation, polypnea, sweating and thermogenesis in response to either 
ambient or hypothalamic temperature changes disappeared during REM sleep. 
The lack of shivering during REM sleep may not be related to muscle atonia, 
since animals which exhibited REM without atonia after pontine lesion still 
failed to show shivering (McGinty and Beahm, 1984). 
1.1.7 Endocrine and neuropeptide secretions 
Sleep-related growth hormone secretion occur during the NREM sleep phase 
(Takahashi et al., 1968; Mitsugi and Kimura, 1985). The episodic secretion 
of prolactin is triggered by sleep onset (Parker et al., 1980), while the 
secretion of cortisol and thyroid-stimulating-hormone are decreased during 
sleep compared with wakefulness (Parker et al., 1980; Mitsugi and Kimura, 
1985). 
Recently it was demonstrated that the episodic release of plasma humoral 
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endorphin is associated with REM sleep (Oksenberg et al., 1980). These data 
together suggest that sleep processes might play an important role in 
regulating the functional reactivity of hormonal and neuropeptide systems. 
1.1.8 Genital response 
Nocturnal penile tumescence (NPT) during sleep has been shown to occur 
during REM sleep in man (Karacan et al., 1966). The female counterpart of 
nocturnal NPT, clitoral erection and increase in vaginal pulse pressure are 
associated with REM sleep (Karacan et al., 1970; Rogers et al., 1985 ). The 
highly predictable occurence of NPT during REM sleep (80-90%) has been used 
to distinguish organic from psychogenic impotence. For example in organic 
impotency associated with diabetes mellitus the REM sleep related NPT is 
greatly diminshed, whereas in psychogenic impotency there is little or no 
reduction in NPT (Karacan et al., 1978). 
1.1.9 Circadian sleep-wakefulness phenomena 
Biological cycles with a period of approximately one lunar day (24 h), 
and that persist in the absence of external environmental cues 
(-zeitgebers-). have been termed circadian oscillations (Aschoff, 1964). In 
animals and human subjects isolated from external time cues, the 
sleep-wakefulness cycle continues to show 
period is only slightly different 
a clearly defined 
from 24 h (Groos, 
rhythm whose 
1984). The 
sleep-wakefulness cycle is therefore a true circadian rhythm which has been 
demonstrated in rats (Borbely, 1982) and in man (Wever, 19?9). Circadian 
influences on sleep-wakefulness in rats affect phase timing and not the daily 
amount of sleep. Lesior. of the suprachiasmatic nucleus abolished the 
sleep-wakefulness circadiar. rhythm but not the daily amount of sleep (Ibuka 
and Kawamura, 1975). Recently the hypothalamic paraventricular nucleus was 
demonstrated to be involved in the maintaince of REM 
(Piepenbrock et al., 1985). 
1 .2 Neural basis oF sleep-wakefulness 
sleep rhythm 
The study of the pathology of viral encephalitis and the associated sleep 
disorders led von Economo (1929) to differentiate two syndromes, a) 
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hypersomnia related to lesions of mesencephalic tegementum and posterior 
hypothalamus and b) sleeplessness in which the lesion affected basal 
forebrain and related striate structures. These observations led to the 
notion of -neural determinism of sleep-waking states-. 
1 .2.1 Neural substrates of wakefulness 
The demonstration of ocular and EEG signs of sleep after the transection 
of the brain stem at the level of the occulomotor nuclei -cerveau isole-
(Bremer, 1935), suggested the presence of an arousal center in the anterior 
third of the pons. Further lesion studies in the rat by Nauta (1946) placed 
the -waking center- at the mesencephalo-hypothalamic junction. Later Moruzzi 
and Magoun (1949) described an arousal system located in the reticular 
formation of the rostral segments of the pons and the midbrain. 
Neural elements rostral to the brain stem reticular formation contributed 
to wakefulness mechanism. One such brain area was localised in the posterior 
hypothalamus (Moruzzi, 1964). This observation is supported by the finding 
that in cerveau isole- preparations in which the locus coerulus and raphe 
nuclei were completely isolated from the forebrair. of the animals, an initial 
period of hypersomnia was followed by behavioural and EEG patterns of 
wakefulness (Hanada and Kawamura, 1981 ). 
1.2.2 Neural mechanism of non-rapid-eye-movement (NREM} sleep 
The initial report of Hess (1927), that electrical stimulation of midline 
thalamic nuclei induce behavioural and EEG signs of sleep was the first 
experimental indication of the existence of an active hypnogenic center. 
Other workers have since demonstrated that stimulation of other brain areas 
can induce behavioural and electrophysiological signs 
al., 1961 ) . Three hypnogenic brain areas may 
of 
be 
sleep (Favale et 
differentiated 
ponte-bulbar raphe system, hypothalamic and thalamo-cortical. 
i) Ponte-bulbar raphe system 
The existence of medullary sleep centers was suggested by reports that 
medullary anesthesia, or cooling, converted sleep EEG into an activated, 
awake, pattern (Berlucchi et al., 1964). EEG synchronisation and behavioural 
sleep were elicited by low frequency stimulation of then. tractus solitarus 
(Favale et al., 1961 ). 
9 
The lesion o~ raphe complex induced, initially, total insomnia followed 
by partial sleep recovery in cats (Jouvet, 1974). However other workers 
failed to implicate raphe nuclei in sleep regulation. For example midbrain 
raphe lesions in rats failed to alter sleep-wakefulness (Bouhuys and van den 
Hoofdakker, 1977). Further~ore unit discharge studies, showed that neurons 
in the dorsal raphe fire less during slow wave sleep compared with waking 
(McGinty and Harper, 1976) and that electrical stimulation of the raphe 
nucleus resulted in arousal (Jacobs et al., 1973). Thus the exact role of 
the raphe nuclei in the regulation of sleep and awake vigilance states 
remains to be clarified. 
ii) Hypothalamic system 
The sleep modulating effect of the hypothalamic area was first suggested 
by the study of Hess (1944) in which he elicited sleep by stimulating the 
preoptic area. Profound insomnia was demonstrated in rats after inducing a 
lesion in the preoptic area (Nauta, 1946). 
iii) Thalamo-cortical NREM sleep system 
Medial thalamic stimulation induce behavioural and EEG signs of sleep 
(Akert et al., 1952). However, the complete destruction of the thalamus 
eliminated only sleep spindles but not slow waves (Naquet et al., 1965). 
Sleep has also been elicited by stimulation of the basal forebrain and 
orbital cortex (Sterman and Clemente, 1962) 
1.2-3 Neural mechanisms of REM sleep 
The pontine brain structures are essential for REM sleep generation. 
However a large body of evidence indicate that different features of REM 
sleep, such as ponto-geniculo-occipital (PGO) spikes, postural atonia and 
neocortical desynchronisation are regulated by different neural substrates 
(Sakai, 1985). The pontine-medullary brain nuclei, locus coerulus and n. 
reticularis magnocellularis are essential for postural atonia during REM 
sleep (Sakai, 1985). 
PGO generators are located in the caudal mesencephalic and rostral 
pontine tegmental area such as brachium 
parabrachialis lateralis, locus coeruleus and n. 
conjunctivum, rostral n. 
laterodorsalis, whereas EEG 
activation during REM sleep involves the n. reticularis magnocellularis 
(Sakai, 1985). 
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1.3 Neurochemical basis oT sleep-wakefulness 
Several endogenous substances, such as the biogenic amines 
(noradrenaline, dopamine, serotonin and $-phenylethylamine), acetylcholine, 
gamma-amino-butyric acid and many neuropeptides (enkephalins, endorphins, 
delta sleep peptide) have been proposed as regulators o~ different vigilance 
states. 
1.3.1 Biogenic amines. acetylcholine and GABA 
i) Noradrenaline (NA) 
Inhibition of tyrosine hydroxylase with a-methyl-p-tyrosine (dMT) or the 
blockade of dopamine-~-hydroxylase with disulfiram suppressed REM sleep, 
reduced waking and decreased the concentrations of NA in the brain (Jouvet, 
1974). These data suggested an involvement of NA in the regulation of waking 
and REM sleep. In contrast ~-MT enhanced REM sleep in the rat (Hartmann et 
al., 1971 ). However, Kafi and co-workers (1977) have demonstrated that only 
high doses of ~-MT, which induced an almost total inhibition of NA synthesis, 
suppressed REM sleep while lower doses facilitated this sleep stage. 
The possible involvement of NA in regulating the sleep-waking states is 
also suggested by the finding that the electrolytic or surgical lesions of 
noradrenergic neurons of the locus coerulus which decreased brain NA levels 
suppressed REM sleep and reduced wakefulness (Jouvet, 1974). In contrast the 
presence of REM sleep was demonstrated inspite low brain NA concentrations 
(Jones et al., 1977). 
In summary, inspite of some contradictory data it appears that 
transmission in NA neurons is involved the modulation of REM sleep and 
wakefulness. 
ii) Dopamine (DA) 
Destruction of the ascending DA-fibers of the ventral mesencephalic 
tegmentum decreased behavioural wakefulness did not alter 
electroencephalographic signs of arousal (Jones et al., 1973). 
In rats the administration of spiroperidol, a DA receptor antagonist, 
produced a dose-dependent increase in total sleep and a decrease of REM sleep 
(Kafi and Gaillard, 1976). Apomorphine (Apo) in doses sufficient to 
11 
stimulate post-synaptic DA receptors decreased total sleep and increased 
waking, whereas low doses of Ape which stimulate DA autoreceptors increased 
REM sleep time (Kafi and Gaillard, 1976). Similarly small doses of DA 
enhanced REM sleep (Hartmann et al., 1975). In addition, the possible 
involvement of various DA receptors in the modulation of alertness has also 
been suggested (Dzoljic and Godschalk, 1978). However. more recent data 
suggest that the activation of D-1 receptors induced arousal, while the 
stimulation of D-2 receptors was associated with sedation and sleep (Gessa et 
al.. 1985). 
It thus appears that the dopaminergic system is involved in the 
regulation of behavioural wakefulness and REM sleep. 
iii) 5-Hydroxytryptamine (5-HT, serotonin) 
Destruction of the raphe system, which contain the cell-bodies of 5-HT 
neurons induced insomnia which was associated with decreased brain 5-HT 
levels in cats (Jouvet, 1974). This finding indicated that 5-HT containing 
neurons in the rostral part of the raphe system are involved in sleep 
mechanisms. 
The involvement of serotonin in NREM sleep induction was also supported 
by the finding that para-chlorophenylalanine (PCPA) which depleted brain 5HT 
decreased both NREM and REM sleep stages in cats and rats (Jouvet, 1974, 
Borbely, 1982). The sleep suppressant effect of PCPA was reversed by the 
administration of 5-HT precursors, tryptophan and 5-hydroxytryptophan. 
The serotonin theory of sleep has been challenged by several reports. 
During chronic studies, sleep in raphe-lesion animals tended to return to 
pre-lesion baseline even though 5-HT levels remained low (Morgane and Stern, 
1974). Brain lesions in rats which reduced brain 5-HT concentrations did not 
alter sleep (Bouhuys and van den Hoofdakker, 1977). Similarly PCPA or a 
chronic tryptophan-deficient diet. both of which can reduce brain 5-HT, had 
no effects in rats (Rechtschaffen et al., 1973; Clancy et al., 1978). In 
addition, serotonin neurons were most active during wakefulness compared with 
any sleep stage (McGinty and Harper, 1976). Similarly, the release of 5-HT 
was highest during wakefulness than when the animals were asleep (Puizzillout 
et al .• 1979). In addition, electrical stimulation of 5-HT rich neurons of 
the dorsal raphe nucleus reduced both NREM and REM sleep stages (Jacobs et 
al., 1973). Although these data are inconsistent with the general postulate 
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that 5-HT is a hypnogenic neurotransmitter, 5-HT neurons may play some role 
in the PGO spikes -gating mechanisms- For example a decreased brain 5HT vas 
associated with the release of PGO spikes into the NREM and awake states 
(Jouvet, 1974). 
Although the role of 5-HT in the regulation of vigilance states is not 
clear it has been recently proposed that 5-HT, released as neurotransmitter 
during waking, might also act as a neurohormone in inducing the synthesis 
and/or the liberation of hypnogenic factor(s). These would be stored, and 
later influence SWS and PS (Jouvet, 1984). 
iv) p-phenylethylamine (PEA} 
P-Phenylethylamine is an endogenous _occurring amine present in the 
mammalian brain. It is the substrate for monoamine oxidase B (MAO-B). The 
structural similarity between PEA and amphetamine (a-methylphenylethylamine) 
has led to the suggestion that PEA may act as an endogenous amphetamine 
(Sandler and Reynolds, 1976). Increasing the concentrations of PEA in the 
brain results in desynchronised EEG pattern and behavioural arousal in 
several mammalian species (Sabelli et al., 1975; Dzoljic et al., 1977). 
Sleep polygraphic studies also demonstrated that both NREM and REM sleep 
stages were suppressed by inhibitors of MAO-B (Cohen et al., 1982). PEA may 
therefore be considered as one of the neuromodulators of wakefulness. 
v) Acetylcholine {Ach) 
Several experiments in animals and human subjects have demonstrated an 
involvement of acetylcholine (Ach) in the induction of REM sleep. 
Both blockade of Ach receptors and inhibition of Ach synthesis using 
atropine, scopolamine or hemicholinium is generally accompanied by a decrease 
in REM sleep. (Domino et al., 1968; Domino and Stawisk, 1970) and reduced 
the frequency of PGO spikes {Henriksen et al., 1972). 
The cholinesterase inhibitor, physostigmine and the muscarinic agonist 
arecoline, facilitated REM sleep at low doses and wakefulness at high 
concentrations (Sitaram and Gillin, 1980). In cats, physostigmine prolonged 
REM sleep periods with increase in rapid eye movements, PGO spikes and atonia 
(Domino et al., 1968). 
vi) Gamma-aminobutyric acid (GABA) 
GABA and it's metabolite gamma-hydroxybutyrate (GHB), appear to possess a 
sleep enhancing effect in several mammalian species. GHB stimulated REM 
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sleep-like state in cats (Stock, 1982). A hypnogenic role for GABA, is also 
supported by the finding that GHB induced EEG synchronisation (Dzoljic et 
al., 1975). Recently L-cycloserine, a substance which can increase brain 
GABA increased NREM and REM sleep stages. However REM sleep was decreased by 
high doses of this substance (Scherschlicht, 1985). 
1.3.2 Neuropeptides and hormones 
i) Endogenous opioid peptides 
Endogenous opioid peptides appear to play an important role in the 
regulation of sleep-wakefulness cycle in both man and animals. However, many 
aspects of the relationship between opioid peptides and sleep have not been 
elucidated yet. Many suggestions related to sleep and opioid peptides are 
derived from stimulation ~~d/or blockade of opioid receptors with drugs as 
morphine and naloxone. 
Morphine is an opium alkaloid named by Serturner in 1803 after Morpheus 
the Roman god of dreams. Electrophysiological studies indicate that this 
name is not appropriate. The intravenous (iv) administration of morphine 
produced a dose-dependent increase in wakefulness, and muscular tension, 
while delta sleep, REM sleep (dreaming period) and sleep efficiency were 
decreased in human subjects (Kay et al., 1969 ). Lewis and co-workers 
(1970), demonstrated that heroin also reduced REM sleep, delayed sleep onset 
increased wakefulness. Thus, stimulation of opioid receptors 
consistently induced insomnia in human subjects. 
Studies in animals are also supportive of a stimulatory role for opioid 
peptides. Diurnal variations in enkephalins, ~-endorphin and dynorphin in 
brain areas important for the regulation of sleep-wakefulness correlate with 
the basic light (rest)-dark (active) cycle in rodents. Thus the peak of 
methionine-enkephalin concentrations in the anterior, medial basal 
hypothalamus, preoptic area and stratium occur during the dark period and 
decline to lowest levels during the light phase (Kumar et al., 1982; Tang et 
al., 1984). ~-Endorphin also reached a peak concentration in the preoptic 
area, pons, medulla oblongata, cerebellum and anterior pituitary during the 
dark phase (Kerdelhue et al., 1983). Similarly immunoreactive dynorphin 
concentrations were highest during the dark phase in the hypothalamus and 
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pituitary (Przewlocki et al., 1983). The diurnal variation in opioid peptide 
concentrations, with peaks during dark periods, suggest that opioid peptides 
might play an important role in priming animals for wakefulness as the dark 
period is kno~ to suppress sleep in rats (Inoue et al., 1984; 1985). 
Other animal experiments have demonstrated that stimulation of opioid 
receptors with opioid peptides or opiates is accompanied by an increased 
wakefulness. Administration of $-endorphin or morphine decreased both NREM 
and REM sleep stages and increased wakefulness in rats and cats (Khazan et 
al., 1967; Echols and Jewett, 1972; King et al. 1981; Scherschlicht et 
al., 1982). Microinjection of (D-Ala2 )-Met5-enkephalinamide (DALA) and 
$-endorphin and des-Y-endorphin into the ventral tegmental area stimulated 
behavioural wakefulness manifested as increased locomotor activity (Broekkamp 
and Phillips, 1979; Stinus et al., 1 980). The lack of a clear 
sleep-influencing effect after intracerebroventricular administration of met-
or leu- enkephalin (Riou et al., 1982) could be explained by the fact that 
these peptides are rapidly metabolised by enkephalinases present in the 
cerebrospinal fluid (Dzoljic et al., 1985). S~udies with DALA a more 
resistant analog of met-enkephalin, have demonstrated an increase in both 
behavioural and EEG wakefulness (Tortella et al., 1978; Dzoljic and Crucq, 
1 979). DALA was found to induce biphasic effects, an initial stupor with 
high voltage slow waves with eyes open and arousal with activated EEG 
pattern. 
Collectively these data indicate that endogenous opioid system play an 
important role in the maintaince of wakefulness in human and animals. The 
mechanism of the arousal effects of opiates and opioid peptides is still not 
clear. It does not appear to involve 5-HT or NA, since pretreatment with 
5-hydroxytyptophan or ~-methyl tyrosine did not alter the arousal effect of 
morphine (Echols and Jewett, 1972). 
An additional point of interest is that diurnal physiological sleep 
period is preceded by intensive grooming which declines prior to diurnal 
arousal phase (Bolles, 1960; Cooper, 1981 ). Following the administration of 
morphine or the synthetic enkephalin RX 783030 grooming episodes were 
extended and sleep reduced. Naloxone however decreased grooming and 
increased sleep (Echols and Jewett, 1972; Cooper, 1981 ) . In contrast, 
naloxone failed to alter sleep-wakefulness (King et al., 1981 ). However, 
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besides this and the fact 
suppress sleep is not fully 
that the mechanism (s) by which opioid/opiates 
understood, it has been proposed that the 
activation of endogenous opioid system impaired the mechanism responsible for 
switching from grooming to sleep (Cooper, 1981 ). 
ii) Endogenous sleep-waking factors 
The concept of sleep factors (hypnotoxins) was initiated by the classical 
experiments of Lengendre and Pieron (1910) in which the cerebrospinal fluid 
{CSF) or serum of sleep deprived donor dog induced sleep in non-deprived 
recipient dogs. Since then several sleep promoting factors have been 
extracted from various tissues and fluids from different animals. Two basic 
approaches have been utilised in the search for the endogenous sleep 
promoting factors:- a) that sleep promoting factor should accumulate during 
prolonged waking and b) that sleep promoting factors should be extractable 
during spontaneous sleep. 
1) Foetor S 
Sleep inducing Factor S is derived from CSF and brains of sleep deprived 
animals (Pappenheimer et al .• 1967). The icv administration of FactorS was 
able to increase delta sleep in rabbits and rats (Pappenheimer et al .• 1967; 
Fencl et al .• 1971 ). Recently Krueger (1983) identified FactorS derived 
from the urine of sleep deprived subjects as a muramyl peptide. The icv 
administration of the synthetic analog of muramyl peptide such as muramyl 
dipeptide (MDP) induced s:eep and fever in rat in a similar fashion to Factor 
S (Krueger. 1983). A slight and slow cumulative increase of SWS in rats were 
observed only after icv administration of MDP during the dark period (Inoue 
et al .• 198~). MDP is present in the cell membrane of bacteria found in the 
urine. Whether MDP is truely the endogenous sleep factor S or derived from 
bacteria floral in the urinary tract remains to be clarified. 
2) Sleep-promoting-substance (SPS) 
The accumulation of sleep-promoting-substances (SPS) in the brain stem 
from 24 h sleep deprived rats has been well documented (Inoue et al. 1985). 
The crude brain stem extracts have been demonstrated consistently to reduce 
locomotor activity and increase total SWS and REM sleep in mice and rats 
(Inoue et al .• 1985). 
Four active components have been separated from the original crude 
extract SPS. A fraction which appears to be identical to the nucleoside 
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uridine, increased both SWS and REM sleep in mice (Komoda et al., 1983) and 
rats (Inoue et al., 1985). An interesting aspect o~ these studies is that 
SPS £acilitates sleep during the dark period but not in the light phase. 
This is in line with the concept that an endogenous sleep substance should 
not induce additional sleep when the physiological demand for sleep has been 
satisfied (Inoue et al., 1985). 
3) REM sleep factor 
REM sleep deprivation appears to induce the accumulation of REM sleep 
factor. The icv administration of CSF from REMSD cats restored REM sleep 
during PCPA induced insomnia in cats (Sallanon et al., 1982) and reversed the 
REM sleep deficit induced by ~-adrenergic blockade (Adrien and Dugovic, 
1984). 
4) Delta sleep-inducing peptide 
Delta sleep-inducing peptide (DSIP) is derived from the brain and GSF of 
animal kept asleep by electrical stimulation of the intralaminar thalamus 
(Monnier et al., 1963). This sleep factor has been identified as nonapeptide 
(Schoenenberg and Monnier, 1977). Central administration of DSIP enhanced 
both NREM and REM sleep stages (Ursin and Larsen, 1983; Inoue et al., 1984). 
However, DSIP injected ip was not effective and tended to increase 
wakefulness (Tobler and Borbely, 1980). The hypnogenic effect of DSIP was 
mostly detected at low doses, while high doses were not effective 
( Scherschlict et al., 1984). In clinical trials :)SIP given intravenously 
increased REM sleep, SWS, spindle sleep, sleep efficiency and decreased the 
frequency of awakening in insomniacs. No sleep rebound was demonstrated 
after drug withdrawal (Schneider-Helmert, 1985). DSIP appear to interact 
with opioid receptors since it could antagonized stress or morphine-induced 
insomnia and the naloxone-precipitated withdrawal in dependent animals 
(Scherschlicht et al., 1984). It thus appear that the pharmacological action 
of DSIP in human and animals depends on environmental conditions and the 
pathophysiology of the organism. 
5) Mesencephalic reticular formation perfusate 
Drucker-Colin (1973) found that the perfusate collected via a push-pull 
cannula from the mesencephalic reticular formation (MRF) of a sleeping donor 
cat decreased sleep latency and increased SWS, without affecting REM sleep. 
Antibodies produced to MFR perfusate peptides collected during REM sleep, 
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decreased REM sleep in cats. 
6) Sleep and waking factors from cerebrospinal fluid (CSF) 
CSF collected from rats during the light period (sleep phase) inhibited 
dark time locomotor activity, while CSF obtained during dark period enhanced 
locomotor activity in the light phase (Sachs et al., 1976). These findings 
are of interest since opioid peptides which are possibly neuromodulators of 
wakefulness, reached peak concentrations during the dark phase (Kumar et al., 
1982; Kerdelhue et al., 1983; Tang et al., 1984). 
7) Growth hormone (GH) 
GH induced a dose-related increase in REM sleep but decreased SWS in both 
animals and man (Drucker-Colin et al., 1975a; Mendelson et al., 1980). 
These data support the suggestion that SWS induced GH release is essential 
for REM sleep induction (Stern and Morgane, 1977). 
1.4 Functions of sleep 
It is generally known that one night sleep loss is followed by very 
annoying symptoms such as fatigue and decreased vigilance. Sleep is often 
assigned a restorative function. Such simplistic a concept would have been 
teneable if sleep was monophasic and accompanied by a near halt of all 
activities. However the discovery that NREM and REM sleep stages were 
distinct states was a tacit indication they may serve different functions. 
Attempts to formulate the roles of sleep in the life of an organism has given 
rise to many theories of the function of sleep. 
1.4.1 Ontogenetic function 
One important observation during ontogenesis is the preponderance of REM 
sleep (active sleep) in human neonates, rat pups and kittens (Roffwarg et 
al., 1966; Jouvet-Mounier et al., 1970). Thus in human neonates REM sleep 
occupies 50 % of the total time and even higher in premature infants. In rat 
pups, kittens and foetal guinea pigs, REM sleep occupy about 60-80 % of the 
total time. These reports indicate that REM sleep may provide the necessary 
endogenous stimuli for brain maturation and development at the critical time 
during which neural elements are being rapidly organised. This line of 
reasoning forms the basis for the -ontogenetic theory" of REM sleep function. 
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This hypothesis is supported by the £act that £rom birth to young adulthood 
human NREM sleep was reduced by 25 % while REM sleep was reduced by 75 % 
(Roffwarg et al., 1966). 
Suppression of active sleep in rat pups with chlorimipramine not only 
altered neural growth and DNA content of some brain areas but also induced 
increased anxiety level and a deficiency in sexual activity of adult animals 
(Corner et al., 1980). Although several reports are supportive of the 
ontogenetic theory of REM sleep, the persistence of this sleep state in adult 
animals is still a puzzle. It has been suggested that REM sleep in adults 
may regulate adaptive behaviours (McGrath and Cohen, 1978). 
1 .4.2 Cognitive function 
In adult animals and humans REM sleep appear to be essential for 
learning, memory and intellectual functions. A recent comprehensive review 
showed a consistent positive relationship between learning and an increase in 
REM sleep (Smith, 1985). Studies based on REM sleep deprivation also suggest 
a functional ~ole in unprepared learning (McGrath and Cohen, 1978). The 
cognitive theory of function of REM sleep is also supported by the clinical 
observations that REM sleep was reduced in mentally retarded patients, 
(Petre-Quadens, 1966). 
1.4.3 Synthetic function 
REM sleep provide a condition for increased polypeptide synthesis 
(Drucker-Colin and Valverde-R, 1982). The peptide synthesis function of REM 
sleep appear to be related it's role in learning and memory. Whilst learning 
increases protein synthesis, substances which can decrease protein synthesis 
disrupts retrival and memory consolidation (Rogers et al., 1974; Flood et 
al., 1975) and suppress REM sleep (Drucker-Colin and Valverde-R 1982). Thus 
REM sleep in adult animals might allow the high turnover of proteins 
necessary for neural reprogramming. 
1.4.4 Restitutive function 
Hartmann (1973) and Oswald (1974) proposed a cerebral or brain 
restitution function for REM sleep. This view is supported by the findings 
that REMSD in human subjects reduced the ability to cope with stressful 
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events (Greenberg et al., 1972). Since REMSD is associated with increased 
motivational behaviour, such as hypersexuality and aggressiveness, REM sleep 
has also been considered to reduce waking drive behaviours (Vogel, 1979). 
The main theory of the function of SWS is that serves bodily restitution 
and musculoskeletal recovery (Hartmann, 1973; Oswald, 1974). A 
behaviourally active day increased SWS stages without altering sleep length 
and REM sleep (Horne and Minard, 1985). In addition GH, which stimulates 
uptake of amino acid into tissue (Korner, 1965), is released by SWS 
(Takahashi et al., 1968). 
1.5 Sleep deficiency 
1.5.1 Total sleep deprivation (TSD) 
TSD in rats and man was followed by sleep rebound. An increase in SWS 
being the most pronounced effect {Borbely, 1982). 
Changes in hormones, enzymes, proteins and some neurotransmitters have 
been observed after TSD. For example TSD induced an increase in the release 
of thyroid stimulating hormone, thyroid 
hydroxylase activity {Sinha et al .• 1973: 
al., 1979). Steriods such as 
hormones, melatonin and tyrosine 
Parker et al •. 1976; Palmbald et 
testosterone, androstenedione, 
dihydrotestosterone and estradiol were decreased after TSD, while the 
pituitary hormones prolactin, follicle stimulating hormone, 
hormone and the adrenal cortex hormone, cortisol were 
{Cortes-Gallegos et al., 1983). 
luteinizing 
not affected 
In rats, TSD increased cerebral GABA levels but decreased glutamic acid, 
glycine, alanine and lysine (Godin and Mandel, 1965). Comparing the effects 
of TSD and REMSD, Panov (1982) found that TSD increased the RNA contents of 
the locus coerulus and n. raphe pontis, while REMSD was associated with a 
decrease in RNA in these brain areas. 
There were no changes in 5-HT and 5-hydroxyindoleacetic acid (5-HIAA) 
levels following TSD (Wesemann and Weiner,1982), whereas there was an 
increase in 5-HT and 5-HIAA after 1 h sleep recovery (Borbely et al., 1980). 
Profound behavioural changes have been demonstrated after TSD. Thus 
there a was decrease in speed of performance, alertness, accuracy (Lubin et 
al., 1974; Loveland and Williams. 1963), motivation, and induced mood 
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deterioration (Johnson, 1969). Prolonged TSD (60-90 h) induced 
depersonalization, hallucination, cognitive disorganisation and loss of 
thought train (Morris et al., 1960). 
Sleep deprivation has also been demonstrated to increase epileptic 
phenomena (Pratt et al., 1968). Little is known of the biological 
consequences of selective SWS deprivation. 
1.5.2 REM sleep deprivation (REMSD) 
1.5.2a Methodological aspects of REM sleep deprivation 
In human REMSD is induced by using the forced arousal technique (Dement, 
1960). The same method can be used in animals. In this method animals are 
implanted with EEG/EMG electrodes for sleep stage monitoring and subsequent 
arousal with sensory stimulus any time the animal entered into REM sleep. 
Selective REMSD using the forced arousal technique presents very serious 
practical problem. Using this technique in rats Morden and co-workers (1967) 
found that the number of awakenings from REM sleep, rose rapidly from 135/8 h 
on first day to 350 on the third day. It became practically impossible to 
arouse animals from REM sleep without curtailing NREM sleep. An ingenious 
method was devised by Jouvet and co-workers (1964) which involves placing a 
cat on an inverted -flower pot- surrounded by a pool of water. The technique 
is based on differences in muscle tone during NREM and REM sleep stages. 
While sitting on the flower pot (=platform, island or pedestal), the animal 
can obtain NREM sleep since muscle tone is present, but during REM sleep 
muscle tone is abolished which causes the animal to wet it's nose or fall 
into the water. The -flower pot- technique was adapted for rats by Cohen and 
Dement (1965) and for mice by Fishbein (1970). REMSD by the flower pot 
technique has obvious advantages over forced arousal: 
a) several animals can be REM sleep deprived at the same time 
b) the experimenter is not required to monitor the sleep 
polygraph 
Both of these. help to reduce the over all cost of the experiments. There 
are however other practical problems associated with using -flower pot- for 
REMSD: 
a) the extent of REMSD 
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b) the technique introduces stress factors such as dampness 
and confinement 
b) there is the additional problem of cleaning the tank and 
animals daily 
Several studies have demonstrated that rats on small platforms (4-7 em 
diameter) were more REM sleep deprived than animals on large platforms 
(11.5-14 em diameter) (Morden et al., 1967; Mouret et al., 1969). These 
studies revealed that REM sleep was also reduced in the large platform 
animals although to less extent. However in these studies, sleep was 
monitored for a few hours rather than the for the whole 4-5 day period. The 
elaborate studies of Mendelson and co-workers (1973; 1974) in which they 
followed sleep polygraph of rats on platforms continously for 4 days have 
clarified this problem. In these reports rat weighing 200-225 g, and 
platform with diameters 6.5 em (REMSD) and 11.5 em (stress group) were used. 
Under these conditions, there was no essential difference in the degree of 
REMSD in the small and large groups during the first 24 h. However in the 
fourth 24 h rats on large platforms has no REM or NREM sleep loss, whereas in 
the small platform group REM sleep was reduced by 50 ~ but NREM sleep was not 
different from baseline. The work of Mendelson's group sets a good standard 
(100 g rat body weight/14.7-15.6 cm2 platform area) for using the -flower 
pot- technique to selectively deprive rats of REM sleep. However rats must 
be maintained for at least 48 h on platforms to achieve REMSD selectivity 
(Vogel, 1975). A corresponding stress group (large platform. 100g rat body 
weight/ 54-61 cm2 platform area) should be added to the experimental design. 
The selectivity of the pedestal technique for REMSD in rats has also been 
recently validated electrophysiologically (Hilakivi et al., 1984). The 
discrepancies often encountered in studies using the -flower pot- technique 
are probably due to the uncritical attitude of some workers in disregarding 
the ratio of animal size to platform diameter or area This problem has 
been fully discussed (Hicks et al., 1977). 
A second confounding factor in the -flower pot- technique of REMSD is the 
stress (dampness and isolation) which is associated with the procedure. It 
has been reported that rats on small platforms lost about 10 ~ of their 
initial body weight compared with control animals in home cages (Dement et 
al., 1967). However, Selye·s indices of stress (weight loss, adrenal 
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hypertrophy and thymus atrophy) and stomach ulceration were not signi~icantly 
different between small (REMSD) and large platform (stress) rats (Mendelson 
et al., 1 974; Levental et al. , 1975; Coenen and van Luij telaar, 1 985). In 
addition there were no differences in blood counts and lympoid tissue 
histology between REMSD and stressed animals (Drucker-Galin et al., 1974). 
Another procedure has also been used to control for stress factors associated 
with REMSD by - flower pot- technique. In this rats are forced to swim in 
water of 18-19 °C, 10 em deep. for 1-2 h daily and thereafter allowed to have 
undisturbed sleep. Adrenal hypertrophy and body weight loss were not 
different between -swimming- rats and animals REM sleep deprived by the 
-flower pot method (Stern et al., 1971; Mendelson et al., 1974). The 
Seyle's stress indices were not essentially different in rats REM sleep 
deprived by the new pendulum procedure or the classical -flower pot-
technique (Coenen and van Luijtelaar, 1985). 
Studies in mice (25 g body weight) also indicate that these animals 
placed on platforms (1-3 em diameter) were more REM sleep deprived than 
animals on large platforms (8-25 em diameter) (Fishbein, 1970; Kitahama and 
Valatx, 1 980). 
In conclusion, these data indicate that the -flower pot- technique is 
still a reliable procedure for REMSD in rodents. The large platform or 
forced swimming are adequate controls for the stress factors associated with 
the flower pot technique for REMSD. In order to reduce the str_ess due to 
confinement, animals in both small and large platforms should be allowed 
daily free locomotion in home cages. 
1.5.2b Biochemical changes after REM sleep deprivation 
i) Serotoninergic system 
It has been demonstrated that REMSD increased the rat brain serotonin 
(5-HT) turnover (Pujol et al., 1968). Weiss and co-workers (1968) also 
confirmed that REMSD increased 5-hydroxyindoleacetic acid (5-HIAA) but 
decreased 5-HT in the brains of rats deprived of REM sleep. Following REMSD 
there was also an increase in the formation of [3H]-serotonin from 
[ 3H]-tryptophan in the brainstem-mesencephalon in rats (Hery et al., 1970). 
In cats there were no alterations in the CSF 5-HIAA levels (Radulovacki, 
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1973) a£ter REMSD, but Livrea and co-workers (1977) demonstrated an increase 
in 5-HIAA in the lumbar CSF of human subjects, deprived of REM sleep. 
However no changes in 5-HT2 binding sites in the frontal cortex of REM sleep 
deprived animals have been demonstrated (Farber et al., 1983). REMSD induced 
changes in 5-HT levels in some brain regions. 5-HT concentrations were 
decreased in the locus coerulus and A5 but increased in frontal cortex and 
ventral tegmentum area without alterations in 5-HIAA concentrations in these 
brain areas (Mattiace et al., 1983). 
ii) Dopaminergic system 
Biochemical analysis shows that REMSD for 4-10 days increased striatal 
dopamine concentrations in rats (Ghosh et al., 1976). without altering lumbar 
CSF concentrations of homovanillic acid (HVA) in human subjects (Livrea et 
al., 1977). Farber and co-workers (1983) found that REMSD increased the 
concentration of dihydroxyphenylacetic acid (DDPAC) in the striatum and 
frontal cortex of rats compared with controls but not with the stress group. 
There were no changes in the binding of pre- or post-synaptic DA receptors. 
iii) Noradrenergic system 
REMSD did not alter noradrenaline (NA) turnover brain of rats (Pujol et 
al., 1968b). However increases in NA turnover after REM sleep rebound was 
reported (Pujol et al., 1968b). Changes in NA and it's metabolite, 
3-Methoxy-4-hydroxyphenylglycol (MHPG), after REMSD have recently been 
demonstrated (Mattiace et al., 1983 ). It was found that REMSD induced a 
decrease in NA and MHPG levels in A5~ and an increase in MHPG levels, without 
affecting NA concentrations in 
dorsal raphe. REMSD did 
the 
not 
striatum, ventral 
alter [ 3H]clonidine 
tegmental area and 
( o:2 ) bin ding sites 
(Mogilnicka and Pile, 1981 ), but decreased$ receptor binding (Mogilnicka et 
al., 1980). However other workers found no changes in$ receptor binding in 
the brain of REMSD animals (Abel et al., 1983). 
iv) Cholinergic system 
A decrease in Ach concentration was observed in the telencephalon of 
REMSD rats (Tsuchiya et al., 1969). There were no alterations in striatal 
concentration of Ach after 96 hr REMSD, whereas a decrease was observed after 
10 days of REMSD (Ghosh et al .• 1969). 
v) Amino acids 
In cats deprived of REM sleep GABA concentrations were increased in the 
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reticular ~ormation, thalamus and frontal cortex, while decreases were 
observed in the colliculi and caudate nucleus (Micic et al., 1969; Karadzic 
et al., 1971 ). Whole brain GABA, glutamic acid, glutamine and threonine were 
not changed in the brain of REM sleep deprived animals (Himwich et al., 
1973). 
vi) Peptides 
Alterations in peptides in some brain areas and the pituitary have been 
observed after REMSD. Thus substance P was reduced in locus coerulus (LC), 
central grey area (CG), medial and dorsal raphe (MR, DR). ventral tegmental 
(VTA), substantia nigra zona compacta (SNC), medial hypothalamus (HMC) and 
caudate areas, whereas somatostatin levels were reduced in DR, CG, SNC and 
VTA. Increases of these peptides were seen in caudate and preoptic areas 
after REMSD (Mattiace et al., 1981 ). $-Endorphin concentrations were 
decreased in the pituitary but increased in the hypothalamus of REM sleep 
deprived rats (Przewlocki, 1984). 
vii) Nucleic acids and protein metabolism 
The neuronal RNA content of the brain stem nuclei, including the 
supraoptic nucleus, was decreased in REM sleep deprived animals (Demin and 
Rubinskya, 1974). Similarly, Panov (1982) found a decrease in RNA 
concentrations in then. raphe dorsalis, n. raphe pontis and locus coerulus 
after REMSD. 
Protein synthesis in some brain areas, such as 
telencephalon, cerebrum and brainstem, was inhibited 
{Bobillier et al., 1974; Shapiro and Girdwood, 1981 ). 
the cerebellum, 
by REMSD in rats 
1.5.2c Electrophysiological changes after REM sleep deprivation 
i) Neuronal excitability 
Several studies have demonstrated that REMSD lowered seizure thresholds 
in both animals and man (Cohen and Dement, 1965; Bergonzi et al., 1973). 
Studies of evoked potentials also indicate that REMSD can modulate neuronal 
excitability. Thus REMSD facilitated recovery of cortical potentials evoked 
by external auditory stimuli (Dewson et al., 1967). Satinoff and co-workers 
(1971) have reported that REMSD increased the paleocortical excitability as 
assessed by evoked potentials, but decreased evoked activities in the 
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hindbrain sensory areas induced by stimulation of hindbrain sensory nuclei. 
It was then suggested that REMSD amplifies cortical responsiveness by 
inhibiting internally generated signals (Satinoff et al., 1971 ). In line 
with the concept that REMSD increased cortical excitability, Bowersox and 
Drucker-Galin (1982) demonstrated that the amplitude of entorhinal cortical 
evoked potentials, following prepyriform cortex stimulation, was increased by 
REMSD. In contrast, photic evoked potentials in the visual cortex was 
decreased after REMSD (van Hulzen and Coenen, 1984). 
increased neuronal excitability. 
In general REMSD 
1.5.2d Behavioural changes after REM sleep deprivation 
i) Nociception 
REM sleep appears to be essential for the regulation of nociception. 
Thus it has been demonstrated that REMSD reduced the pain threshold to 
noxious electrical stimulation. The decrease in pain threshold 
evident 96 hr after the termination of REMSD (Hicks et al., 1978; 
ii) Waking motor and motivated behaviours 
was still 
1979a). 
An increase in the number of cage crossings has been demonstrated during 
the 10-15 min after REMSD (Albert et al., 1970; van Hulzen and Coenen, 
1981 ). REMSD reduced neophobia, increased exploration, ambulation and 
rearing (Hicks et al., 1979b; Moore et al., 1979; Mogilnicka et al., 1985). 
Shock provoked aggression was facilitated in REM sleep deprived animals 
(Hicks et al., 1979). 
Hypersexuality, manifes~ed as compulsive mounting behaviour was provoked 
by chronic REMSD in cats (Dement et al., 1967). 
REMSD lowered the threshold and frequency for intracranial self 
stimulation (ICSS) at the medial forebrain bundle site in rat (Steiner and 
Ellman, 1972), whereas ICSS of the lateral hypothalamic area was not altered 
(Marti-Nicolovius et al., 1984). 
Further support for the concept that REM sleep is involved in 
motivational behaviours, comes from the report that REMSD also enhanced food 
competition between male rats (Hicks et al., 1981 ). 
iii) Learning and memory 
Several authors have studied the effect of REMSD on learning and memory, 
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however most of the results are conflicting (Smith, 1985). For example Stern 
(1971) reported that REMSD induced a clear learning deficit in one way active 
and passive avoidance tests but Albert and co-workers (1970) could not 
confirm this observation. Similarly, retention of a condition passive 
avoidance response was disrupted by REMSD (Leconte and Bloch, 1970). These 
conflicting findings appear to be due to the lack of proper control of rat 
body weight to platform size, so that there may have been no great difference 
in REMSD between small (REMSD) and large (control) platform animals (Hicks et 
al., 1977). However another group using a different procedure for REMSD 
found no alteration in the two way shuttle avoidance response in animals 
deprived of REM sleep (van Hulzen and Coenen, 1979). 
Contradictory effects of REMSD on memory in humans have also been 
reported. REMSD had no effect on memory (Chernik, 1972) whereas a decrease 
in memory was reported after REMSD (Fowler et al., 1973). In another study 
REMSD decreased creativity (divergent or flexible thinking) but improved 
serial memory task (Lewin and Glaubman, 1975). 
Although some inconsistency exist in literature, the weight of evidence 
suggests that REMSD may disrupts complex and unprepared forms of learning, 
especially those with emotional components (McGrath and Cohen, 1978). 
1.5.3 Clinical aspects of REM sleep deprivation 
i) Depression 
Sleep pattern is generally altered in depressive conditions. The major 
disturbance in depression involves shortened REM latency, an extended first 
REM period, increased REM density/activity and a decrease in delta sleep 
(Kupfer et al., 1984). 
It has been demonstrated that REMSD can improve some forms of endogenous 
but not reactive depressions (Vogel et al., 1975; Vogel, 1980). In these 
elaborate clinical studies, endogenous depressives that were not improved by 
REMSD did not respond to imipramine. Summarizing the recent literature, 
Vogel (1983) outlined evidence for the therapeutic efficacy of REMSD in a 
subtype of endogenous depression: 
a) REMSD and imipramine have similar therapeutic efficacies 
b) The usefulness of antidepressant was related to their 
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ability to induce substained and large REMSD 
c) Drugs such as barbiturates, alcohol, diphenylhydantoin, 
opiates and amphetamines can induce short-lasting REM 
sleep reduction. In addition tolerance to REM sleep 
inhibiting properties of these drugs develops rapidly, 
usually within one week or less. These drug possess no 
antidepressant properties. 
d) The behavioural effects of REMSD in animals, such as 
increased sexuality and aggressiveness, are opposite to 
the behavioural alterations present in human depression. 
In addition, wide range of typical and atypical antidepressants, induced 
selective REM sleep suppression with little or no alterations in NREM sleep 
stage (Scherschlicht et al., 1982). 
It has become generally accepted that REMSD can improve some forms of 
endogenous depression and may in fact be part of the mechanism by which 
antidepressants exert their therapeutic action (Vogel, 1983). The 
antidepressant action of REMSD was long lasting up to 21 days. 
ii) Schizophrenia 
Unlike depression, REMSD did not alter schizophrenic symptoms (Vogel and 
Traub, 1968; Gillin et al., 1974). It was also demonstrated that REM sleep 
rebound, following REMSD, was exaggerated in schizophrenics. Thus it was 
suggested that active schizophrenia was associated with a decrease in REM 
sleep need (Gillin et al., 1974). 
iii) Epilepsy 
Sleep disturbances and seizure phenomena often co-exist in human 
epileptics. For example, patients with grand mal seizure had reduced REM 
sleep, whereas NREM sleep stage 2 was increased (Besset, 1982). Sleep 
pathology in epileptics with cortical or deep temporal foci was mainly in the 
form of a decrease in NREM stages 3 and 4 (Montplaisir et al., 1982). 
In addition to sleep disturbances associated with epilepsies, some 
seizure activities occur preferentially in sleep while others occur in 
wakefulness 
The paroxysmal discharges in petit mal epilepsies were facilitated by 
sleep onset and awakening. Two subgroups of petit mal seizure exist, 
classified according to the distribution of epileptic discharges during 
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sleep. In one group epileptic discharges occur during REM sleep. while in 
the second group paroxysmal discharges were suppressed during REM sleep (Ross 
et al., 1966; Billiard, 1982). 
REMSD has been demonstrated consistently to lower the seizure threshold 
in experimental animals (see section 1 .5.2c). In human epileptics, REMSD 
facilitated seizure activity during the night after REMSD was stopped 
(Bergonzi et al., 1973). In another report selective SWS deprivation, rather 
than REMSD, was more effective in provoking epileptic attacks in pycnoleptic 
children (Becket al., 1977). 
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CHAPTER 2 
ENDOGENOUS OPIOID PEPTIDES 
2.1 Nomenclature and classification 
The discovery that electrical stimulation of the periaqueductal gray area 
induced morphine-like analgesia (Akil et al., 1972) led to the search for an 
endogenous opiate ligand. Later Hughes and co-workers (1975; 1975a) 
isolated an endogenous compound from the brain with pharmacological 
properties similar to that of morphine. They termed this endogenous 
morphine-like compound enkephalin (from en kephalos, in the head). From the 
initial extract named enkephalin two related pentapeptides which differ only 
in the carboxyl terminal amino acid were identified (Hughes et al., 1975b), 
namely methionine-enkephalin (met-enkephalin, met-ENK) and leucine-enkephalin 
(leu-enkephalin, leu-ENK). Since the initial discovery of endogenous opioid 
pentapeptides by Hughes and co-workers, several other ligands with opioid 
activity have been isolated from various tissues in different animals (Hughes 
et al., 1980; Bloom, 1983). 
Other peptides with opioid activity were found in the pituitary and 
designated ~-endorphin (Li and Chung, 1976), ~. andY-endorphin (Bradbury et 
al., 1976; Ling et al., 1976). 
Opioid peptides which are extended leu-ENK sequences have been extracted 
from the pituitary. Goldstein and co-workers (1979) isolated and named a 
pituitary opioid peptide as dynorphin1_13 . In the same year another opioid 
peptide, a decapeptide described as -big- leu-ENK was named ~-nee-endorphin 
(Kangawa and Matsuo, 1979). Other peptides include dynorphins 1_8 , 
dynorphin 1_17 and ~-nee-endorphin (Minamino et al., 1980; 1981; Goldstein 
et al., 1981 ). Several other morphine-like substances have been isolated 
from various animal tissues for example, ~-casomorphins derived from £-casein 
(Brantl et al., 1979) and humoral (H) endorphin (Sarne et al., 1978). 
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2.2 Metabolism of endogenous opioid peptides 
At present three classes of endogenous opioid peptides have been 
described : ~-endorphin, enkephalins and dynorphin. There is now sufficient 
evidence that these opioid peptides originate from three different precursors 
(Hughes et al., 1980). 
2.2.1 Biosynthesis 
i) ~-endorphin 
Biochemical evidence in the literature indicate that $-endorphin and 
other non-opioid such as corticotropin, 
$-melanocyte-stimulating hormone (MSH), p-lipotropin and adrenocorticotrophic 
hormone (ACTH) are formed from a common precursor termed pro-opiomelanocortin 
(POMC)(Hughes et al., 1980; Bloom, 1983). The POMC derived peptides are 
produced by proteolytic cleavage of the lipotropin. 
ii) Enkephalins 
Several studies have demonstrated that enkephalins are produced from a 
ribosomally synthesized protein precursor termed pro-enkephalin (Hughes et 
al., 1980). This pro-enkephalin contains one copy of leu-ENK and six of 
met-ENK (Noda et al., 1982). Several synthetic analogues of enkephalins have 
been produced for example, D-Ala2 -met5-enkephalinamide (DALA) and 
D-Ala2-D-Leu5-enkephalin (DADLE). 
Structures of enkephalins 
Met-enkephalin:- Tyr-Gly-Gly-Phe-Met 
Leu-enkephalin:- Tyr-Gly-Gly-Phe-Leu 
iii) Dynorphin 
Dynorphin and ~-nee-endorphin are derived from a protein precursor termed 
prodynorphin (Kakidani et al., 1982). 
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2.2.2 Biodegradation of enkephalins 
Opioid peptides are inactivated by several peptidases present in 
mammalian tissues. 
i) Soluble aminopeptidases 
Aminopeptidases degradate enkephalins by cleavage of the Tyr-Gly peptide 
bond. The major metabolite following aminopeptidases hydrolysis of 
enkephalins is tyrosine (Hambrook et al., 1976). These enzymes can be 
inhibited by bestatin. 
ii) Enkephalinase A 
Enkephalinase A is a dipeptidyl-carboxypeptidases which cleaves Gly-Phe 
peptide bond in enkephalins. Enkephalinase A is sensitive to inhibition by 
thiorphan, phosphoramidon and kelatorphan (Hudgin et al., 1981; Waksman et 
al., 1985). 
iii) Enkephalinase B 
Enkephalinase B is a dipeptidyl~aminopeptidase which inactivates 
enkephalins by cleavage of Gly-Gly amide bond (Gorenstein and Synder, 1979). 
No selective inhibitor of this enzyme has been demonstrated. 
iv) Angiotensin-converting-enzyme (ACE) 
Similar to enkephalinase A, ACE hydrolyses Gly-Phe amide bond of 
enkephalins, but does not appear to play an essential role in in vivo 
situations (Erdos et al., 1978). Captopril which is an inhibitor of this 
enzyme, does not modulate the enkephalinergic system in vivo. 
Enkephalins are inactivated in vitro by all four enzymes mentioned above. 
However, the soluble amino peptidases and enkephalinase A appear to be 
involved in the biotranformation of synaptic enkephalins in vivo. 
Knowledge of the biological mechanisms involved in the inactivation of 
$-endorphin and dynorphin is still poor. 
2.3 Opioid receptors 
The existence of specific opioid receptors in the mammalian brain was 
demonstrated simultaneously by three groups (Pert and Snyder, 1973; Simon et 
al .. 1973; Terenius, 1973). Later studies of Martin and co-workers (1976) 
on the effects of opiates in spinal dogs indicated the heterogeneity of 
opioid receptors. The three different opiates, morphine, 
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ethylketocyclazocine (EtKGZ) and N-Allylnorphenazocine (SKF 10047) produced 
distinct syndromes. Based on this behavioural study the existence of three 
different opioid receptors have been suggested: ~ (mu) for morphine, x 
(kappa) for EtKCZ and o (sigma) for SKF 10047 (Martinet al., 1976). 
The concept of multiple opioid receptors was also confirmed and extended 
in studies utilizing, guinea-pig ileum and mouse vas deferens bioassays and 
autoradiography (Lord et al., 1977). These authors concluded like Martin and 
co-workers that morphine showed preference for ~-receptors. However the 
enkephalins, especially leu-ENK, interacted mainly with the opioid receptors 
designated 6-receptors. £-Endorphin was equipotent at ~ and 6-receptors. 
More recently two subtypes of ~ receptor designated ~, and ~2 have been 
suggested (Pasternak et al., 1983). Enkephalin bind to ~, and 6 sites, while 
morphine bind to both ~, and ~2 sites. Dynorphins show preference for 
x-receptors (Garzon et al., 1983). The relative affinities of some opiates 
and opioid peptides for opioid receptors are shown in table I. 
Table I: Relative affinity oT ligands Tor opioid receptors 
(modified oTter Hughes et al. 1980, Garzon et al., 1983) 
Ligands Receptors 
" 
6 
' 
met-ENK ++ +++ + 
leu-ENK + +++ + 
~-endorphin +++ +++ + 
mer hine +++ + + 
dynoruhin(1-17) ++ + +++ 
EtKCZ + + +++ 
Naloxone +++ + + 
Key: +=low, ++=moderate, +++=high 
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Similarly a heterogeneity of opioid receptors has been demonstrated in 
the human brain (Maurer et al .• 1983)- The importance of multiple opioid 
receptors for physiological functions of endogenously released opioid 
peptides is not yet clear. The opioid receptor types possible involved in 
the pharmacological effects of opiate and opioid peptides are indicated in 
table III 
2.3.1 Opioid receptor distribution in the brain 
The idea that the various opioid receptors are differentially distributed 
in various brain areas is supported by considerable body of evidence (Atweh 
and Kuhar. 1983)- Recently the distribution of~ and o-opioid receptors in 
the rat brain was assayed 
[2 ]-Tyr-D-Ala-Gly-NMet-Phe-Gl-ol 
by using 
(DAGO) 
highly 
for 
selective ligands 
#-receptor and 
(DTLET) for 6-receptors (Quirion et al., 
1983b). Table II show the relative preponderance of ~ and 6-receptors in 
some brain regions. 
The distribution of x-receptors in the rat brain is similar to that of 
#-receptors (Quirion et al., 1983a). 
2.4 Physiological implications 
peptides 
2.4.1 Analgesia 
of regional distribution of opioid 
Opioid peptides are present in high concentrations in the brain areas 
(periaqueductal gray area, intralaminal thalamic nuclei and raphe nuclei) and 
spinal cord (laminae I and II of dorsal horn) related to pain and analgesia 
(Hokfelt et al., 1977; Simantov et al., 1977). Electrical stimulation of 
the PAG and pituitary has been demonstrated to induce naloxone reversible 
analgesia (Akil et al., 1972; Yanagida et al., 1985) possibly by causing the 
release of opioid peptides. A lesion of the arcuate nucleus, which reduced 
8-endorphin levels in the hypothalamus, periventricular area and in the 
neurointermediate lobe of the pituitary was reported to decrease pain 
threshold (Millan et al., 1980). REMSD decreased the pain threshold to 
noxious electric shock (chapter 1, section 1 .5.2b) and the pituitary 
8-endorphin concentrations (Przewlocki. 1984). The involvement of 
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Table II: Relative preponderance oT opioid receptors in some 
brain areas (modified after Quirion et al. 1983b) 
Brain region Receptors 
n. accumbens ++++ ++ 
frontal cortex ++ ++ 
layers II IV of cortex +++ 
layers V IV of cortex + +++ 
caudate putamen ++++ +++ 
olfactory tubercle + +++ 
se tum + 
thalamus +++ 
am dala +++ 
h othalamus + 
hi us ++ + 
habenula ++++ + 
interpeduncular nucleus +++ + 
central r ++ + 
cerebellum 
n. tractus solitarius +++ + 
locus coerulus +++ 
dorsal horn (suinal cord) +++ + 
Key: -=absent, +=low, ++=moderate, +++=high, ++++=very high 
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endogenously released opioid peptides in the regulation of nociception is 
also supported by other reports. The icv administration of enkephalinase A 
inhibitors, thiorphan and phosphoramidon which are known to potentiate the 
enkephalinergic system (Hugdin et al., 1981) increased the pain threshold 
(Carenzi et al., 1981; Rupreht et al., 1983). ~-Endorphin given centrally 
induced analgesia in both animals and human subjects (Loh et al., 1976; 
Hosobuchi and Li, 1978). 
2.4.2 Locomotor activity 
Opioid peptides are present in high concentrations in caudate nucleus, 
putamen, globus pallidus (basal ganglia), amygdala, substantia nigra and in 
the ventral tegmental area (Khachaturian et al., 1983). These brain areas 
are important in the regulation of skeletal muscle tone and locomtor 
activities (Chambers et al., 1971 ). In Parkinsonism a deficiency of ENK in 
the pallidum, putamen, substantia nigra and the ventral tegmental area has 
Agid and Javoy-Agid, 1985). Opioid been demonstrated (Taquet et al., 1983; 
receptors in the substantia nigra and striatum have been implicated in 
opiate-induced muscular rigidity and catalepsy (Turski et al., 1983). 
The administration of $-endorphin or met-enkephalin icv can stimulate 
morphine-like catalepsy in rats (Bloom et al., 1976; Chang et al., 1976). 
Similarly, the administration of an enkephalinase inhibitor. thiorphan also 
induced hypotonic immobility in mice (Chaillet et al., 1983). The medial 
preoptic area, n. accumbens, periaqueductal gray area, and anterior 
hypothalamus are particularly sensitive to the cataleptogenic effects of 
opiates and opioid peptides (Tseng et al., 1980; Winkler et al., 1982). 
However the administration of low doses of morphine or opioid peptides icv 
stimulated locomotor activity, wet-dog-shakes (WDS) and body scratching in 
rats (Wei et al., 1977; Brady and Holtzman, 1981 ). Microinjection of 
morphine, enkephalins and ~-endorphin into ventral tegmental area or n. 
accumbens produced behavioural changes characterised by sniffing and grooming 
interrupted by bursts of locomotor activity. These stimulant actions of 
opiates and opioid peptides were naloxone-reversible (Pert and Sivit, 1977; 
Kelly et al., 1980; Stinus et al., 1980). Similarly naltrexone-sensitive 
WDS, grooming and body scratching were also observed following icv 
administration of the enkephalinase inhibitor phosphoramidon (Rupreht et al., 
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1983). 
2.4.3 Temperature 
A role ~or endogenously released opioid peptides in temperature 
regulation is suggested by the report that administration of an enkephalinase 
inhibitor, thiorphan or met-enkephalinamide could induce a 
naloxone-reversible hypothermia. This hypothermia due to endogenously 
released opioid peptides involves the preoptic and the anterior hypothalamic 
areas (Stanton et al., 1985). Similarly central administration of 
~-endorphin induced hyperthermia in low concentrations and hypothermia in 
high doses (Tseng et al., 1980). 
2.4.4 Feeding 
Endogenously released opioid peptides appear to 
(Jalowiec et al., 1981 ). Systemic or intracerebral 
regulate feeding 
administration of 
morphine, ~-endorphin or enkephalins facilitated food consumption (Grandison 
et al., 1977; Jalowiec et al., 1981; Tepperman and Hirst, 1983). Opioid 
peptides in the hypothalamic brain area are particularly important for the 
regulation of feeding behaviours (Przewlocki et al., 1983). 
2.4.5 Respiratory and cardiovascular system 
Local application of morphine and enkephalins to the dorsa-rostral 
surface of the pons in cats selectively decreased the frequency of 
respiration, whilst tidal volume or the response to carbon dioxide were left 
unchanged or increased (Hurle et al., 1983). Morphine was less effective 
than enkephalin in reducing the frequency of respiration. However, naloxone 
can easily reverse 
hypoventilation (Bowman 
morphine-induced respiratory depression nnd 
depression 0~ 
nnd 
r~spiration 
Rand, 1980) but not the enkephalin-induced 
(Pazos and Florez, 1983). It was suggested that 
both both ~ and 6-receptors are involved in the respiratory depressant 
actions of opioid peptides and opiates. 
A decrease in blood pressure after the application of met-enkephalin to 
the ventral surface of the brain stem in the cat has been reported (Florez 
and Mediavilla, 1977). The microinjection of met- or leu-enkephalin into the 
brain produced either hypertension or hypotension, depending on the site of 
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injection. It has been suggested that t~o types of opioid receptors exist in 
the medulla. A naloxone-resistant receptor which mediate vasopressor 
responses and naloxone-sensitive receptor which mediates 
responses (Fuxe et al., 1979). 
vasodepressor 
2.4.6 Sexual behaviour 
The possible involvement of endogenous opioid peptides in sexual 
behaviour is suggested by several authors. A decrease in sexual function in 
narcotic addicts has been reported (Crowley and Simpson, 1978). Whereas 
opiate withdrawal may be associated with premature ejaculation, spontaneous 
erection in men and sexual arousal in women (Parr, 1976). Pretreatment of 
opiate-dependent rats with enkephalinase inhibitors thiorphan or phelorphan 
stimulated penile-licking during naloxone-precipitated withdrawal (Dzojlic et 
al .• in preparation). A similar activation of penile licking was observed 
following the administration of another enkephalinase inhibitor 
phosphoramidon to REMSD animals (unpublished observation). However central 
administration of ~-endorphin or D-Ala2 -met5-enkephalinamide reduced mounting 
behaviour in normal, non-dependent male rats (Meyerson and Terenius, 1977; 
Gessa et al .• 1979). These inhibitory actions of opioid peptides on sexual 
behaviour were blocked by naloxone and naltrexone. Further studies are 
necessary for the clarification of the role of different opioid receptors in 
sexual behaviours. 
2.4.7 Neuronal excitability 
Accumulating evidence indicate that both opium alkaloids and opioid 
peptides are capable of exerting an inhibitory or a facilitatory action on 
cerebral excitabiltiy. The administration of large doses of morphine, icv or 
systemically. can induce convulsive behaviours in mice and rats (Gilbert and 
Martin, 1975; Snead and Bearden, 1982). Pretreatment with subconvulsant 
doses of morphine can block the convulsant effect of morphine and enkephalins 
(Urea and Frenk, 1983; Dzoljic, 1982). Similar pretreatment with morphine, 
$-endorphin and [D-Ala2-D-Leu5]enkephalin (DADLE) also antagonised 
electroshock-induced seizures (Puglishi-Allepra et al., 1984; Berman and 
Alder, 1984). This anticonvulsant action of opiates and opioid peptides was 
blocked by naloxone (Berman and Alder. 1984). Recent data indicate that the 
55 
6-opioid receptors mediate the epileptic actions of enkephalins, whilst 
~-opioid receptors are involved in the anticonvulsant actions of opioid 
peptides (Dzoljic and vd Poel-Heisterkamp, 1982; Frenk. 1983; Haffmans and 
Dzlojic, 1983). The target area of this action appear to be in the limbic 
area (Henriksen et al., 1978), particularly in the hippocampus (French and 
Siggins, 1980; Haffmans et al., 1983; 1984). However in the fluorothyl 
seizure test both 6 and ~ opioid receptor agonists appear to be 
anticonvulsants (Tortella et al., 1985). It does appear that exogenously 
administered opioid peptides may have both pro- and anti-convulsant actions 
depending on the experimental conditions. The role of pro- and 
anti-convulsant opioid systems in human epilepsies is still unknown. 
2-4-8 Tolerance and dependence 
Similar to morphine the development of tolerance to opioid peptides has 
been reported (Wei and Loh, 1976; Tseng et al., 1977). Interestingly, in 
animals tolerant to the ~agonist sufentanyl, a 6-opioid receptor agonist 
DADLE was still able to induce analgesia and catatonia (Schulz et al., 1981 ). 
This might indicate the lack of cross-tolerance between ~ and 6 receptor 
agonists. It also appears that an organism can develop tolerance and 
dependence to endogenously released opioid peptides. Namely naloxone 
precipitated an opiate-like abstinence syndrome after chronic stress or 
Chester, 1 982; Bean and Vaught, enkephalinase inhibition (Christie and 
1984). Social interaction appear to activate endogenous opioid peptides 
resulting in an opioid-like -social dependence-. Isolation or social 
separation provoked symptoms such as vocalisation and irritability. Symptoms 
induced by social isolation could be reduced by morphine and potentiated by 
naloxone (Panksepp, 1981 ). 
The possible involvement of changes in endogenous opioid peptides in the 
process of opiate dependence is not clear. However, chronic morphine 
treatment increased the activity of a high affinity enkephalinase (Malfroy et 
al., 1978). Enkephalinase inhibiton attenuated some symptoms of opiate 
withdrawal in morphine dependent animals (Dzoljic et al., in preparation). 
An increase in protein synthesis also appears to be involved in the 
mechanism of tolerance to opiates. Several drugs with the common ability to 
inhibit protein synthesis reduce the development of tolerance and dependence 
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to morphine (Bowman and Rand, 1980). In addition, it has been reported that 
the development of opiate dependence is associated with an increase in the 
synthesis of secretory proteins in the pons-medulla and striatum-septum (Retz 
and Steele, 1983). These brain areas are functionally involved in opiate 
tolerance and dependence (Herz. 1978). The hippocampal CA~ area also appear 
to be modulate both opioid and opiate-withdrawal WDS (Isaacson and Lanthorn. 
1981). 
Some pharmacological actions of opiates or opioid peptides and the 
possible brain areas involved have been described in this section. Table III 
summarises some pharmacological actions of opioid peptides/opiates and the 
receptor types involved. 
2.5 Drugs and behavioural states affecting endogenous opioid peptides 
2.5.1 Neuropeptidase inhibitors 
Potentiation of enkephalinergic activities following the inhibition of 
neuropeptidases have been demonstrated under several experimental conditions. 
For example kelatorphan a potent inhibitor of enkephalinase increased 
met5-enkephalin (met-ENK) levels in rat striatum and blocked the 
biodegradation of exogenously administered enkephalins (Waksman et al., 
1985). Similarly thiorphan an enkephalinase inhibitor A (Hudgin et al. 
1981 ), given alone, or in combination with bestatin (peptidase inhibitor), 
elevated in vivo striatal and midbrain met-ENK levels and induced 
naloxone-reversible analgesia (Zhang et al., 1982; Yaksh and Harty, 1982). 
Phosphoramidon, another potent inhibitor of enkephalinase A (Hudgin et al., 
1981 ), induced naltrexone-sensitive analgesia (Rupreht et al., 1983) and 
insomnia (see chapter 3). Other neuropeptidase inhibitors such as bestatin 
and leucinal increased brain met-ENK levels and ~-endorphin-stimulated 
analgesia (Waksman et al., 1985; Davis et al., 1983). In addition, naloxone 
precipitated some behaviours characteristic of the opiate abstinence syndrome 
in rats after chronic inhibition of enkephalinase (Bean and Vaught, 1984). 
These reports indicate that inhibition of some neuropeptidases can induce 
increases in opioid peptides with concomitant alterations in behaviour. The 
effect of peptidase inhibitors on the brain concentrations of other opioids 
such as ~-endorphin and dynorphin, still remains to be established. 
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Table III: Pharmacological effects of opiates and receptor subtypes 
involved (modified after Trends in Pharmacol. Sci., vol 6 
centre'fold) 
Pharmacological actions Rece12tors 
" 
0 X 
"1 0 
SU:Qras:Qinal analgesia 
stress-induced analgesia .. 
eu haria .. ? ? 
d s haria ? ? 
sedation ? 
catale s 
increased locomotion •• ? ? 
decreased locomotion ? 
tolerance .. 
withdrawal signs .. 
ictal EEG S:Qiking ? ? 
anticonvulsant .. .. ? 
h erthermia 
h othermia 
res:Qirator;y de:Qression 
Key: **"'direct involvement, *=possible involvement, ?=not 
established -=not involved 
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2.5.2 Centrally acting drugs 
i) Narcotic analgesics 
Morphine elicited a decrease in plasma ~-endorphin but elevated the 
concentration of this peptide in whole brain (without the cerebellum) and in 
the pituitary (Bruni et al., 1985). The analgesic effect of morphine has 
been ascribed, partly, to the release of endogenous opioid peptides (Schlen 
and Bentley, 1980). However, prolonged morphine administration (>1month) 
decreased enkephalin levels in the striatum and pituitary. A similar 
reduction in ~-endorphin contents were demonstrated in the septum, midbrain 
and pituitary (Herz et al., 1980a). Plasma concentration of 8-endorphin-like 
material was reduced in heroin addicts (Ho et al., 1980). In contrast, other 
studies failed to demonstrate changes in brain enkephalin concentrations 
after acute or chronic morphine treatment or naloxone-precipitated withdrawal 
(Fratta et al., 1977; Wesche et al., 1977). Chronic (10 days) treatment 
with morphine increased enkephalinase activity and ~-opioid receptors in the 
striatum (Takashi et al., 1981 ). 
ii) Neuroleptics 
Chronic administration of the antipsychotic drugs haloperidol and 
chlorpromazine increased the formation of Y-endorphin 
des-Tyr 1-Y-endorphin in brain slice. Other central depressants such as 
phenobarbital and promethazine did not alter the concentrations of these 
opioid peptides (Davis et al., 1984). However, neuroleptic therapy has been 
reported to increase plasma- and CSF- endorphin activity in chronic 
schizophrenics (Emrich et al., 1980; Naber et al., 1984). 
Met-enkephalin levels in the striatum and nucleus accumbens were elevated 
after chronic treatment with the antipsychotic drugs such as clozapine, 
haloperidol and reserpine. The non-cataleptogenic neuroleptic such as 
clozapine was less effective in elevating met-ENK levels (Hong et al., 1980). 
The clinical relevance of the neuroleptic induced alterations in opioid 
peptides is not yet clear. 
iii) Antidepressant drugs 
Antidepressant drugs such 
iprindole provoked a 
as cloimipramine, desimipramine, amitriptyline 
selective increase in met5-enkephalin-like 
immunoreactivity in the striatum and nucleus accumbens (De Felipe et al., 
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1985). An increase in ~-endorphin contents in the pituitary and hypothalamus 
has also been reported after treatment with some antidepressants (Pzewlocki, 
1984). 
Interestingly, antidepressant drugs decreased plasma ~-endorphin in 
depressive patients in correlation with therapeutic activity (Rapisarda and 
Bongiorno, 1982; Genazzani et al., 1984). 
iv) Anaesthetic agents 
The analgesia induced by nitrous oxide has been attributed to enhanced 
endorphinergic transmission since it could be attenuated by naloxone and 
naltrexone (Yang et al., 1980). In addition, morphine attenuated whilst 
naloxone potentiated nitrous oxide withdrawal convulsions in mice {Manson et 
al., 1983). Recently nitrous oxide has been demonstrated to increase met-ENK 
levels in the CSF o~ rats (Quack et al., 1985). Chronic ethanol consumption 
decreased the release o~ enkephalin in the striatum inducing supersensitivity 
o~ 6-opioid receptors, but reduced the af~inity o~ the ~-opioid receptors 
(Lucchi et al., 1984). The role of endogenous opioid peptides in the 
pharmacological actions of anaesthetic agents is not fully understood. There 
is however the idea that the analgesic and eurphoric effects of nitrous oxide 
are due partially to release o~ endogenous opioid peptides. 
v) GABA and benzodiazepins 
GABA and muscimol were found to decrease potassium-evoked release of 
striatal met-ENK. In a parallel in vivo study, acute administration of 
benzodiazepines such as diazepam decreased met-ENK levels in the striatum but 
increased them in the hypothalamus. The drug induced enhancement of 
enkephalin was rapid in onset (2-5 min) (Herz et al., 1980b). 
vi) Drugs modulating 5-HT system 
The serotonin releaser, ~en~luramine increased met-ENK and B-endorphin 
contents in the hypothalamus but not in the ~rontal cortex, hippocampus and 
brain stem (Harsing et al., 1982). Conversely, PCPA and 5-7-DHT which 
depletes 5-HT levels in the brain reduced B-endorphin concentrations in the 
hypothalamus, thalamus, and brain stem but not 
administration of these substances did not 
peptide (Harsing et al., 1982). 
in the pituitary. Acute 
alter brain contents of this 
The clinical signi£icance o~ changes in opioid peptides induced by drugs 
interfering with GABA and 5-HT system is not clear. 
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2.5.3 Stress 
Abundant evidence suggests that endogenous opioid peptides are modulated 
by various stress regimens. Electroshock induced a naloxone-reversible 
analgesia and motor inhibiton (Nabeshima et al., 1985). A parallel increase 
in brain enkephalin levels and the pain threshold has been demonstrated after 
electric shock (Madden et al., 1977). Electroconvulsive shocks, ~hich are 
associated with a naloxone-reversible postictal analgesia and catalepsy (Urea 
et al., 1981 ), elevated preproenkephalin mRNA and enkephalin concentrations 
in the hypothalamus and limbic area (Yoshikawa et al., 1985). Painful 
stimuli, such as arthritis or injecting formalin into rat paws, increased 
enkephalin levels in the brain (Cesselin et al., 1980; Kuraishi et al., 
1981 ). Immobilisation stress or forced s~imming did not alter dynorphin 
concentrations in the cortex and hypothalamus, whereas tail-pinch stress 
enhanced dynorphin in these brain regions (Morley et al., 1982). The 
pituitary gland contains high concentrations of opioid peptides (Prze~locki 
et al., 1983; Kerdelhue et al., 1983; Tang et al., 1984), which are 
released during acute stress exposure (Guillemin et al., 1977), probably 
indicating an involvement of pituitary opioid peptides. along ~ith ACTH, in 
the stress response. 
2.6 Role of opioid peptides in psychopathology 
Several behavioural actions of opioid peptides studied in animals 
suggested possible implication of endogenous opioid peptides in human 
psychopathology. 
and limbic areas 
In addition opioid peptides are present in the 
where they are well placed to modulated 
motivation and emotions. 
2.6.1 Opioid peptides and depressive states 
brain stem 
vigilance, 
In several studies an increase in plasma and CSF $-endorphin levels in 
depressive conditions have been demonstrated (Risch, 1982; Genazzani et al., 
1984), while in other reports no changes in the plasma or CSF concentrations 
of $-endorphin were found (Naber et al., 1982). Patients with endogenous 
depression were also more tolerant to pain than normal volunteers (Davis et 
~-. 1979). Antidepressant drugs decreased plasma $-endorphin in parallel 
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with their therapeutic activity (Rapisarda and Bongiorno, 1982; Genazzani et 
al.. 1984). These data indicate that excess of opioid peptides may be 
involved in the pathogensis of some forms of endogenous depression. 
2.6.2 Opioid peptides in schizophrenia 
The icv administration ~-endorphin elicited rigid immobility in rats. 
This observation led Bloom and co-workers (1976) to propose that an excess of 
central opioid peptides might be involved in the pathophysiology of 
schizophrenia. In contrast, Jaquet and Mark (1976) proposed that ~-endorphin 
may have a neuroleptic-like therapeutic action, since this peptide induced 
extrapyramidal-like ridigity. These propositions have given rise to two 
schools of thought ie i) that excess and ii) that a de~iciency o~ opioid 
peptides, underlie schizophrenia. Increased ~-endorphin levels in CSF of 
schizophrenic and manic patients were reported by some workers (Rimon et al., 
1980), and naloxone appeared to reduce psychotic symptoms (Watson et al., 
1978). However other authors could not con~irm these findings (Naber et al., 
1981 ). Direct biochemical evidence that excess opioid peptides are secreted 
in schizophrenia or that opiate antagonist helps in this disorders is at 
best tenous. ~-Endorphin either slightly accentuated (Gerner et al., 1980) 
or allevated some symptoms of schizophrenia (Kline et aL 1977)-
Des-Tyr1-Y-endorphin (DTYE) decreased psychotic symptoms in schizophrenics 
(Verhoeven et al., 1979). In contrast other workers did not ~ind any 
therapeutic effects following DTYE (Emrich et al., 1980). However 
antipsychotic drugs such as haloperidol and chlorpromazine increased the 
formation of Y-endorphin and des-Tyr 1-Y-endorphin in vitro in animal brain 
slice (Davis et al., 1984). Plasma and CSF ~-endorphins were inceased in 
schizophrenics , although there was no correlation between changes in plasma 
opioid peptides and the therapeutic e~~ects of the antipsychotic drugs 
(Emrich et al., 1980; Naber et al., 1984). 
Evidently the role of endogenous opioid peptides in the psychotic 
disorders needs further clarification. 
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,PART II: MUTUAL INTERACTIONS BETWEEN NORMAL SLEEP AND ENDOGENOUS OPIOID 
SYSTEM 
CHAPTER :S 
ENDOGENOUS OPIOID PEPTIDES AND SLEEP 
ABSTRACT 
Intracerebroventricular (i.c.v.) administration of the enkephalinase 
inhibitor phosphoramidon {25-100 ~g) induced a dose-related decrease in 
non-rapid eye moevement sleep (NREMS) and rapid eye movement sleep (REMS) 
time, with a corresponding increase in wakefulness. 
The local application of phosphoramidon (1-25 ~g) into the locus coerulus 
(LC) or periventricular gray (PVG) substance also inhibited both NREMS and 
REMS, and increased wakefulness. 
Pretreatment with naltrexone (0.1 mg/kg, i.p. 15 min prior) 
significantly reduced the phosphoramidon-induced insomnia. Similarly, local 
application of naltrexone (10 #g/brain area) also decreased the insomnia 
induced by the administration of phosphoramidon into the PVG or LC. 
These findings indicate that endogenous opioid peptides are important 
modulators of wakefulness. 
INTRODUCTION 
Few studies on this subject with controversal results have been 
performed. It has been found that ~-endorphin had an arousal effect in rats 
(Havlicek et al., 1978). This was confirmed in cats by i.c.v. 
administration of 0.5 #g B-endorphin (King et al., 1981 ). However other 
authors did not find significant changes in sleep parameters after i.c.v. 
injection of either #g B-endorphin, met-enkephalin or leu-enkephalin (Riou 
et al., 1982). The doses, species and way of administration of the 
corresponding opioid peptide might be of crucial importance in the 
interpretation of these results. For example, recent data indicate that 
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REM sleep stages using the combined EMG, ECoG and hippocampal EEG parameters 
(Fig 1 ). REM sleep episodes were identified by the appearance of low voltage 
ECoG fast waves, hippocampal theta pattern and EMG silence. NREM sleep was 
characterised by high voltage slow ECoG waves together with low EMG. Awake 
stage was identified by high EMG and fast low voltage ECoG. 
Drug 
Phosphoramidon (Peninsula Lab) dissolved in saline was administered 
i.c.v. (maximum volume 2 ~1. i.c.v. or 1 ~1 local application). Naltrexone 
hydrochloride (Endo Lab) was administered intraperitoneally (i.p.) dissolved 
in saline. 
Statistics 
Statistical analysis was done using paired Student t-test. 
significance was accepted at P-value of 0.05 or less. 
RESULTS 
Intraventricular administration of enkephalinase inhibitor 
Statistical 
The administration of phosphoramidon increased wakefukness whilst it 
decreased the NREM and REM sleep stages in a dose-dependent manner (Fig 2). 
The sleep suppressant effect of phosphoramidon was associated with 
behavioural signs of excitation such as head shakes and body scratching. The 
opiate antagonist naltrexone administered in a dose range which did not alter 
the sleep-waking pattern in the control animals (0.1-0.5 mg/kg) antagonized 
phosphoramidon-induced insomnia (Fig 2). 
Nicroinjection of enkepholinase inhibitor 
Locus coerulus 
of phosphoramidon (1-25 ~g) into the locus coeruleus Application 
decreased NREM 
Naltrexone (10 
insomnia. 
40-50% and REM 20-27% sleep stages in a dose-related manner. 
~g. 5 min prior) decreased the phosphoramidon-induced 
Central gray substance 
Phosphoramidon (1-25 ~g) injected into the periventricular gray (PVG) 
substance of the brain induced a significant increase in wakefulness. This 
arousal effect of phosphoramidon was decreased by naltrexone (10 ~g. 5 min 
prior) (Fig 3). 
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Figure 3: £nkephalinase inhibition and wakefulness in rats. Each bar is 
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naltrexone. 
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DISCUSSION 
The results o~ this study indicate that specific enkephalinase inhibitor 
phosphoramidon induces both NREM and REM sleep suppression. Naltrexone 
antagonized the sleep suppressive action of enkephalinase inhibitor which 
suggests that the increased wakefulness induced by phosphoramidon is mediated 
by activation of opioid receptors. 
The local application of phosphoramidon into specific brain regions 
induced naltrexone sensitive insomnia in this study. This is consistent with 
the fact that microinjection of opiates into these brain areas induces 
behavioural excitation (Jacquet and Wolf, 1981 ). The above data might 
indicate that an endogenous opioid system, particularly the 
system plays an important role in the maintaince 
enkephalinergic 
of wakefulness. 
Furthermore, a number of pathological conditions such as stress, anxiety and 
other psychic disturbances, in which an increase wakefulness is a common 
symptom, are known to be associated with increased endorphin levels. It is 
therefore conceivable that activation of the enkephalinergic system might 
constitute the common mechanism underlying various sleep-waking disturbances. 
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CHAPTER 4 
STAGES OF VIGILANCE AND ENKEPHALIN-INDUCED SEIZURES 
ABSTRACT 
The effects of different sleep-wakefulness stages on enkephalin-induced 
seizure phenomena were studied in the rat by recording the electrical 
activities of the pari etc-frontal cortex, dorsal hippocampus and 
submandibular/nuchal muscle. 
Administration of [D-Ala2 ]-Met-enkephalinamide (DALA, 10 ~g/2~1. i.c.v.) 
induced electrographic signs of seizure during SWS, REM sleep and 
wakefulness. The DALA-induced epileptiform activities in ECoG, EMG and 
hippocampus were significantly higher during wakefulness compared with any 
sleep stage. REM sleep significantly inhibited DALA-induced ECoG spiking 
activity compared with SWS and wakefulness. Similarly SWS decreased the ECoG 
spiking activity compared with wakefulness. 
It is suggested that an enkephalinergic system may be involved in the 
ethiopathogenesis of epilepsy of the -awaking type- particularly that with 
petit mal characteristics. 
INTRODUCTION 
The clinical finding that some epileptic attacks occur more frequently 
during the day and others at night suggests an influence of the sleep-waking 
cycle on the occurence of epilepsy (Janz, 1962). Although some types of 
epilepsy occur mainly during sleep, their occurence is not facilitated evenly 
by different sleep stages. 
Recent data indicate that intracerebroventricular administration of 
enkephalin in rats induces electrographic and behavioural epileptic phenomena 
(Dzoljic et al., 1979; Urea et al., 1977), and it has been suggested that 
endogenous opioid peptides play a modulatory role in the pathogensis of 
epilepsy (Dzoljic and Poel-Heisterkamp, 1982). 
In order to understand better the relationship between stages of 
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vigilance, endopioids epilepsy, we studied the effect of 
sleep-wakefulness cycle on enkephalin-induced seizures. 
MATERIALS AND METHODS 
Adult, male Wistar rats weighing 175-200 g were used. For the recording 
of the electrocorticogram, silver screw electrodes were threaded into the 
bone overlying the frontal and parietal cortices. The electromyogram (EMG) 
was recorded from the neck and/or submandibular muscles. Hippocampal 
electrical activities were recorded from the CA1 region by means of 
bilaterally implanted stainless steel electrodes. A new cannula system 
intracerebroventricular administration of provided the possibility of 
[D-Ala2-met]-enkephalinamide (DALA, 10 ~g./2 ~1) in unrestrained rat, in any 
stage of vigilance, with full external control upon the rate of flow, 
frequency and volume of drug injection. All rats were allowed at least a 
7-day recovery period before experiments commenced. Animals were maintained 
-~~d~r constant light/dark periods (light phase 06.00-22.00 h) and experiments 
were carried out between 12.00-16.00 h to avoid variations due to changes in 
the circadian rhythm. Results were analysed statistically using paired 
Student's t-test. Statistical significance was accepted at P-value of 0.05 
or less. 
RESULTS 
DALA given during wakefulness induced electrographic signs of seizure 
phenomena such as cortical or hippocampal spikes and myoclonic contractions 
in the muscles. However, the same dose of DALA given during slow wave sleep 
(SWS) or rapid eye movement (REM) sleep produced significantly less 
electrographic signs of seizure (Fig 1 ). The REM sleep stage proved more 
resistant to DALA -induced seizure compared to SWS. However, the inhibitory 
effects of SWS and REM sleep on hippocampal spikes and myoclonic contractions 
were not significantly different from each other. The most prominent 
DALA-induced epileptic phenomena were observed during the awake stage. 
Behavioural phenomena such as -wet-dog-shakes- and -fall down- were 
associated with the epileptic burst in the EEG and appeared only if DALA was 
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Figure 1: The effect of vigilance states on enkephalin (DALA, 
introcerebrovenrticularly)-induced seizure phenomena during the 4 time 
periods after drug administration. Only spikes up to 200 and 4DO~V in the 
ENG and ECoG. respectively were counted. Each vertical bar is mean±S.E 
spikes for 7 rats. Note that sleep, particularly REM sleep significantly 
reduced the intensity of the electrographically registered epileptic 
phenomena in the cortex, hippocampus(hipp) and the submandibular muslces 
(sub.m.). 
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given during wakefulness and not during the SWS and REM sleep. 
DISCUSSION 
It is known that REM sleep deprivation increases neuronal excitability 
(Cohen and Dement, 1965). However, the results of this study indicate that 
normal REM sleep and to a lesser extent SWS decrease significantly all the 
electrographic signs of DALA-induced seizure phenomena in the hippocampus. 
cortex and submandibular/neck muscle when compared to wakefulness. The cause 
of the inhibitory effect of sleep on enkephalin-induced seizure is not clear. 
However the epileptic properties of enkephalin can be antagonized only by 
anti-petit mal and not anti-grand mal drugs (Snead and Bearden, 1980). 
Furthermore, petit mal paroxysm occurs mainly during wakefulness or 
sleep-waking transition period (Janz, 1962). This clinical observation is in 
accordance with the inhibitory effects of sleep on enkephalin-induced seizure 
demonstrated in this study. Therefore, a possible involvement of an 
endogenous opioid system in the ethiopathogenesis of epilepsy of the -awaking 
type-, particularly those with petit mal characteristics should be 
considered. In addition, this experimental model can be used as a reliable 
tool in future studies of the relationship between different vigilance states 
and drug-modulated neuronal excitability. 
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PART III: MUTUAL INTERACTIONS BETWEEN DISTURBED SLEEP AND OPIATE/OPIOID 
PEPTIDES 
CHAPTER 5 
REM SLEEP DEPRIVATION DECREASES THE ANTINOCICEPTIVE PROPERTY OF 
ENKEPRALINASE-INHIBITION, MORPHINE AND COLD-WATER-SWIM 
ABSTRACT 
1) In this study, the e~£ect of REM sleep deprivation (REMSD) or chronic 
stress was investigated on three analgesic procedures as follows: 
enkephalinase-inhibition (phosphoramidon), morphine 
induced antinociceptions. 
and cold-water-swim 
2) REMSD (96 hr) completely abolished the analgesic effect of phosphoramidon 
(250 ~g. i.c.v.), morphine (20 ~g. i.c.v.) and 5 min cold-water-swim (5° C, 
cold). 
3) Rats exposed to chronic stress regimen did not show any tolerance to the 
analgesic effect of phosphoramidon or CWS. 
4) These data indicate that REMSD can decrease pain threshold, probably by 
altering enkephalinergic and other transmitter systems. 
5) It is suggested that pharmacological manipulations and/or pathological 
conditions which decrease REM sleep might affect the efficacy of opiate and 
other analgesic procedures. Additional clinical studies are necessary to 
clarify the relationships of REMSD and pain threshold in human. 
INTRODUCTION 
The inhibitory action of opiates and opioid peptides on REM sleep is well 
documented (Khazan et al., 1967 King et al., 1981 ), while the effect of 
REM sleep or REM sleep deprivation (REMSD) on opiate activity is less clear. 
However, it is kno~ that the episodic release of humoral endorphin is 
associated with REM sleep (Oksenberg et al., 1980) and REM sleep inhib~ts 
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neuronal excitation induced by exogenously administered enkephalins 
(Ukponmwan and Dzoljic, 1983). These data suggest that phasic changes during 
the sleep-waking cycle can modulate response to opiates and opioid peptides. 
In order to clarify further the relationship between sleep disturbances 
and opiates, the effect of REMSD on the antinociceptive property of morphine 
and enkephalinase inhibitor phosphoramidon was investigated. Phosphor amidon 
potentiates enkephalinergic activity in the brain 
biotransformation of enkephalins (Hudgin et al., 
by decreasing the 
1981). By using 
phosphoramidon and morphine, it was possible to study the effect of REMSD on 
analgesic effects induced by endogenous opioid pepides and exogenously 
administered opiates. 
Since it is known that REMSD can reduce the pain threshold to noxious 
electrical stimulation (Hicks et al., 1979), we included in this study, the 
relationship between REMSD and physically induced antinociception such as 
cold-water-swim analgesia. 
MATERIALS AND METHODS 
All experiments were performed on male adult Wistar rats weighing between 150 
and 175 gat implantation. 
Surgery 
For the intracerebroventricular (i.c.v.) administration of drugs. stainless 
steel, guide cannula was stereotaxically directed 1 mm above the lateral 
ventricle. The injection cannula protruded 1 mm below the guide cannula into 
the ventricle. At least 5-7 day recovery period was allowed before 
experiments were commenced. Throughout this study, all animals were kept in 
a constant environment chamber with a light-dark cycle 12 hr (light period 
09.00-21.00 h) and a room temperature 22±1°C. Food and clean drinking water 
were available ad libitum. 
Three groups of experiments 
phosphoramidon, (ii) the effect 
cold- water-swim (CWS) analgesia. 
were performed (i) analgesic effect of 
of morphine on pain threshold, (iii) the 
The animals in each experiment were 
divided into three groups as follows: REM sleep deprived, chronic stressed 
and non-stressed (controls) rats. Each group was submitted to CWS procedure 
or treated either with phosphoramidon or morphine. 
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REM sl&ep deprivation (RENSD) 
REMSD was carried out using the conventional -flower pot- technique 
previously described (Mendelson et al., 1974). In order to avoid the problem 
of unequal REMSD {Hicks et al., 1977), we used platforms whose area 
corresponded to the rat body weights (14 cm2 : 100 g). Each rat was REM 
sleep deprived for 96 hr continously. In the present set up, the animals had 
free assess to food and clean drinking water. Throughout the REMSD, the 
water in the tank was changed regularly (11 .00-12.00 hr) once every 24 hr. 
During the period of cleaning the animals were allowed free locomotion in 
individual cages, for 1 hr during which rats were kept awake manually. 
Stress 
The rats in this group were forced to swim in water 17-18 °C and 7 em for 
2 hr daily (11 .00-13.00hr) for 4 days. The animals were then allowed 
spontaneous amount of sleep for the remaining period of the day (22 hr). 
Weight loss in the stress and REMSD groups were not different from each 
other. 
Control 
These animals were housed singly and allowed to have spontaneous amounts 
of sleep. 
Cold-water-swim analgesia (CWS) 
CWS was produced using the procedure described by Bodnar and Sperber 
(1982), with a slight modification in duration of swimming and water 
temperature. The rats were forced to swim for 5 min in water 5 °C. Pain 
threshold was determined before and then at 30, 60, 90 and 120 min after CWS. 
The measurement of pain threshold was commenced 30 min after CWS to allow 
animals to become completely dry. 
Phosphoramidon or morphine analgesia 
This was induced by intracerebroventricular administration of these 
substances 
Determination oT nociception 
Pain sensitivity test was carried out between 13.00 and 16.00 h according 
to the analgesiometric method (Randall and Seltto, 1957). The nociception 
was expressed in the form of analgesiometric scores (AMS) g mm- 2 pressure. 
The cut off value was maintained at 500 g mm- 2 to avoid damage to the paw. 
Response to pain in this study is measured by squeak or paw-withdrawal. 
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Animals which scored above 150 g mm-2 during control testing were not used 
for further experimentation. In all three groups: REMSD, stress or controls 
baseline pain threshold vas 
phosphoramidon was administered. 
af~er drug treatment. 
Drugs 
measured before 
Nociception was then 
saline, morphine 
followed for 2 
or 
hr 
The following drugs were used in this study, morphine hydrochloride 
(Merck) and phosphoramidon (Peninsula Lab) were administered dissolved in 
saline. A maximum of 2~1 was given i.c.v. over a period of 10 sec. 
Statistical analysis 
The significance of differences between the analgesic scores obtained 
after different treatments was evaluated by Student t-test. once a one way 
analysis of variance (ANOVA) had revealed that the samples represented 
different populations (Steel and Terrie, 1980). Statistical significance was 
accepted at P-values of 0.05 or less (two tailed). 
RESULTS 
The effect of REMSD on the analgesia induced by enkephalinase-inhibition 
The intracerebroventricular (i.c.v.) administration of phosphoramidon 
(250~g/~l) in control or stressed animals caused an increase in pain 
threshold during the first 30 min after drug treatment. 
Phosphoramidon-induced analgesia in control and stressed animals was 
accompanied by signs of central excitation such as wet-dog-shakes, excessive 
grooming, hypermotility. The antinociceptive action of phosphoramidon was 
ccmpletely abolished by REMSD (Fig 1) 
The effect of REMSD on morphine analgesia 
Morphine (20 ~g/2~1. i.c.v.) induced profound analgesia in both control 
and stressed animals. The antinociceptive action of morphine was lowered in 
stressed group compared with control animals. The increase pain threshold 
induced by morphine lasted about 2 hr during which rats remained quiet with 
decreased motility (not evaluated). REMSD completely antagonized analgesia 
(Fig 2). 
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e---.11 Control + phosphoramidon (ph) 
o---o Chronic stress + ph 
o---o REMSD + ph 
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Figure 7: The inhibitory effect of REM sleep deprivation (R£MSD) on 
phosphoramidon (ph) induced analgesia. Each point is mean± S.£.M for 
control n=26, REMSD n=25 and stress n=19 groups. The number of animals 
receiving phosphoramidon in each group are as follows:- control+ ph=8, REMSD 
+ and stress + Note that phosphoramidon given 
intracerebroventricularly induced an increase in pain threshold in both 
control and stressed animals. This analgesic effect of phosphoramidon was 
completely abolished by REMSD. 
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o----e Control + morphine ( mo) 
o---o Chronic stress + mo 
o----c REMSD + mo 
60 120 
Time {min) 
Figure 2: The inhibitory effect of REM sleep deprivation (REMSD) on morphine 
(mo) analgesia. Each point is mean ± S.E.M for control n=26, REMSD n=25 and 
stress n=19. The number of animals receiving morphine in each group are as 
follows: control + mo=10, REMSD + mo=10 and stress+ mo=B. Note that 
morphine induced long lasting increase in pain threshold was completely 
abolished by REMSD. 
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The effect of cold-water-swim (CWS) analgesia 
The pain threshold was significantly higher in rats exposed to 
cold-water-swim compared to control or stressed animals. This CWS analgesia 
was antagonized by REMSD (Fig 3). 
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Figure 3: The antagonistic effect of REM sleep deprivation (REMSD) on 
cold-water-swim analgesia (CWS). Each point is mean± S.E.M for control 
n~26, RENSD n=25 and stress n~19. The number of animals submitted to CWS in 
each group was n=6. Note that CWS analgesia in both control and stress 
groups was completely abolished in REM sleep deprived rats. 
DISCUSSION 
It is of interest to note that the antinociceptive activity of 
enkephalinase-inhibitor (phosphoramidon) and morphine was completely 
abolished in REM sleep deprived rats. The phosphoramidon-induced analgesia 
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(Rupreht et al., 1983) is probably due to the known enkephalinase inhibition 
and the consequent increase in the enkephalinergic activity (Hudgin et al., 
1981 ). In addition it has been demonstrated that the enkephalinase inhibitor 
thiorphan also possesses antinociceptive activity (Roques et al .• 1980). 
The mechanism by which REMSD antagonizes the analgesic effect of 
phosphoramidon is not clear. However, one possible explanation could be that 
animals deprived of REM sleep might have a lowered level in functional 
activity of the enkephalinergic system. This possibility is consistent with 
the known inhibitory effects of REMSD on peptide synthesis (Shapiro and 
Girdwood, 1981 ). Consequently, the reduced activity of opioid peptides in 
the brain may decrease pain threshold. Previous studies have demonstrated 
that a decrease in peptide synthesis did not alter morphine analgesia (Loh et 
al., 1969; Tulunay and Takemori, 1974). Hence the decreased antinociceptive 
action of morphine cannot be explained by a possible reduction in opioid 
peptides. 
Therefore, another explanation such as alteration in other 
neurotransmitter(s) which are known to modulate nociception should be 
considered. For example it has been demonstrated that increase of 
dopaminergic activity and/or decrease serotoninergic and cholinergic 
transmission which occur during REMSD (Farber et al., 1983; Mogilnicka et 
al., 1981; Tsuchiya et al., 1969) could antagonize the analgesic activity of 
opiates (McGilliard and Takemori, 1979; Garlitz and Frey, 1972; Tulunay et 
al., 1976). These data suggest that changes in biogenic amines might be an 
important factor in the inhibitory action of REMSD on analgesia induced by 
exogenous and endogenous opioid peptides. 
The physiological basis of CWS analgesia is not known, but due to the 
lack of cross-tolerance with morphine produced antinociception, it appears to 
be mediated by a non-opioid mechanism (Bodnar et al. 1978) e.g the GABAergic 
system which has been shown to play a role in analgesia in response to 
environmental stress (Skerritt et al., 1981 ). Changes in the activity of 
GABA system were demonstrated in REMSD animals (Micic et al., 1967). 
Relative to controls, no change in threshold to noxious paw pressure was 
observed in chronically stressed animals. Thus stress does not appear to 
play an important role in the slight decrease in pain threshold observed in 
rats deprived of REM sleep. 
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Finally, although the mechanism by vhich REMSD decreases pain threshold 
is not certain, some clinical consequences should be considered. Namely, it 
should be expected that pathological conditions and/or drug treatments 
accompanied with decrease REM sleep could modify the therapeutic 
effectiveness of opiates and other analgesic procedures. Additional clinical 
studies are required to clarify the significance of REM sleep in maintaince 
of normal nociception in human. 
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CHAPTER 6 
ANALGESIC EFFECT OF ENKEPHALINASE INHIBITION IS MODULATED BY MONOAMINE 
OXIDASE B AND REM SLEEP DEPRIVATION 
ABSTRACT 
Both the MAO-B inhibitor deprenyl (2.5-10 mg/kg, i.p., 60 min prior) and 
the MAO-B substrate E-phenylethylamine (PEA, 40 ~g. i.c.v.) potentiated the 
analgesic action of the enkephalinase inhibitor phosphoramidon (250 ~g. 
i.c.v.) in animals allowed normal sleep. The enhancing effect of PEA on 
phosphoramidon analgesia was further potentiated by deprenyl (5 mgjkg, i.p.) 
pretreatment. Deprenyl 5mg/kg, i.p.) or PEA (40 ~g. i.c.v.) given alone 
did not induce analgesia in animals allowed undisturbed sleep. 
REM sleep deprivation (REMSD) decreased the basal pain threshold and 
abolished the analgesic effect of phosphoramidon. The administration of 
deprenyl and/or PEA failed to restore the analgesic effect of phosphoramidon 
in REM sleep deprived animals. 
The results indicate that excess PEA has a stimulatory effect on the 
analgesic activity of endogenously released enkephalins in rats allowed 
undisturbed sleep but not in REM sleep deprived animals. 
It is suggested that the failure of phosphoramidon to induce analgesia 
after REMSD, is probably due to a functional insufficiency of an 
enkephalinergic system. 
INTRODUCTION 
Two forms of monoamine oxidase (MAO) are present in the mammalian brain, 
MAO-A and MAO-B. Serotonin, dopamine and noradrenaline are preferred 
substrates for MAO-A, while MAO-B shows selectivity for E-phenylethylamine 
(PEA) (Yang and Neff, 1974; Garrick and Murphy, 1980). Several lines of 
evidence suggested that inhibition of MAO activity increased the 
pharmacological effects/toxicity of opiates in patients (Taylor, 1962) and 
animals (Iwamoto and Ho, 1972; Boden et al., 1984), although this effect was 
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only seen when both MAO-A and MAO-B were inihibited (Jounela et al., 1977). 
Nevertheless some interactions between MAD-E inhibitors and opiates/opioid 
peptides have been reported. For example, an inhibition of MAO-B or excess 
of PEA (the substrate for MAD-B) potentiated the analgesia induced by 
exogenously administered opiates/opioid peptides (Fuentes et al., 1977; 
Garzon et al., 1980). In addition, some pharmacological actions of PEA can 
be modulated by opioid receptor blockade (Kubota et al., 1982; Dourish and 
Cooper, 1984) suggesting a possible interaction between PEA and opioid 
receptors. 
This study was undertaken to clarify the relationship between MAO-B and 
the analgesic effect of endogenous (synaptic) enkephalins following 
administration of an enkephalinase inhibitor to rats allowed undisturbed 
sleep and animals subjected to REMSD. In these experiments REM sleep 
deprived rats were used because it has been shown that both MAO-B inhibitors 
and REMSD possess antidepressant activity (Mann and Gershon, 1980; Vogel et 
al., 1980) and modulate the analgesic action of opiates/opioid peptides 
(Garzon et al., 1980; Ukponmwan et al., 1984a). 
MATERIALS AND METHODS 
Adult, male Wistar rats weighing 150-175 g were used in this study. 
Drugs were injected intracerebroventricularly (i.c.v.), when required, via a 
stainless steel cannula implanted in the lateral ventricle. Correct 
placement of i.c.v. cannula was verified using the procedure recently 
described (Ukponmwan et al., 1985). A 4 day recovery period was allowed 
after cannula implantation before the experiments were commenced 
REM sleep deprivation 
REMSD(96 h) and the corresponding stress-control, were carried out as 
~reviously described (Ukponmwan et al. 1984a) using a modification of the 
method of Mendelson (1974). This method is known to selectively deprive rats 
of REM sleep after 96 h (Mendelson et al., 1974). Throughout this study, all 
animals were maintained in a constant environment room with an ambient 
temperature of 22±1°C and automatically regulated light-dark cycle of 12 h 
(light period 09.00-21.00 h). Food and clean drinking water were available 
ad libitum. 
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Assessment oT nociception 
Pain sensitivity to noxious paw pressure was assessed between 13.00-16.00 
h using to the analgesiometric technique of Randall and Selitto (1957). 
Nociception was measured 15, 30, 60 and 120 min after drug administration and 
expressed as analgesiometric scores (AMS) g mm-2 pressure. The cut off value 
was measured by a squeak or paw-withdrawal. Animals scoring above 150 g mm-2 
during control testing were not used for further experimentation. 
Drugs 
The following drugs were used in this study: phosphoramidon (Peninsula 
Laboratories, San Carlos, CA. USA), deprenyl (Chinoin, Budapest, Hungary) and 
B-phenylethylamine (PEA, Sigma, St. Louis, Mo, USA). Drugs for i.c.v. or 
i.p. administration were dissolved in physiological saline and administered 
in volumes of 2~1 or 500~1 respectively. Since the half-life of PEA in tr.e 
brain is known to be very short (Wu and Boulton, 1975), this substance was 
given 5 min after phosphoramidon and the pain threshold was measured 10 min 
later. 
Statistics 
The significance of differences between the analgesic scores obtained 
after different treatments was evaluated by Duncan's new multiple range test, 
once a one way analysis of variance (ANOVA) had revealed that samples 
represented different populations (Steel and Terrie, 1980; Saxena, 1985). 
Statistical significance was accepted at P-values of 0.05 or less (two 
tailed). 
RESULTS 
A significant difference in the analgesic scores across the various 
groups and time intervals was found after the administration of 
phosphoramidon (Fig 1 ). Similarly the effect of pretreatment with deprenyl 
and/or E-phenylethylamine (PEA) on phosphoramidon induced analgesia was 
significant across the treatment groups (Fig 2, p<0.01 ). 
The eFFects oF deprenyl and(or E-phenylethylamine on phosphoramidon- induced 
analgesia in animals allowed normal sleep 
The administration of the enkephalinase inhibitor phosphoramidon (Hudgi~ 
et al. 1981) (250 ~g. i.c.v.) significantly increased the pain threshold to 
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Figure 1: The effect of d&pronyl on the analgesic action of the enkephalinase 
inhibitor phosphoramidon in rots allowed undisturbed sleep. Nociception was 
determined by withdrawal of hind paw from pressure stimulation (modified 
Randall-Selitto test). Each point is mean ± SEm at each time point. The 
number of animals per treatment group is indicated in parenthesis. Note that 
deprenyl (2.5-10mg/kg,ip, 60 min prior) potentiated the analgesic effect of 
phosphoramidon (250~ icv) in a dose-related manner. (*) indicate significant 
difference from saline pretreated group (p<O.OS). 
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paw pressure. The most prominent analgesic effect was registered between 
15-30 min after drug administration (Fig 1) 
Deprenyl the MAO-B inhibitor, (2.5-10 mg/kg, i.p., 60 min prior) 
potentiated the analgesic effect of phosphoramidon in a dose-related manner 
(Fig 1 ). Similarly the MAO-B substrate, PEA, (40~g. i.c.v., 5 min 
post-phosphoramidon) also enhanced the phosphoramidon-induced analgesia (Fig 
2. p <0.05). Pretreatment with deprenyl (5 mg/kg, i.p., 60 min prior) 
further increased the potentiating effect of PEA (40 ~g. i.c.v.) on the 
analgesic action of phosphoramidon (Fig 2, p<0.05). Neither deprenyl (5 
mg/kg, i.p.) (Fig 2, p>0.05) nor PEA (40 #g, i.c.v., data not shown) induced 
analgesia in animals allowed undisturbed sleep. 
The effects of deprenyl and P-phenylethylamine on phosphoramidon-induced 
analgesia in REM sleep deprived animals 
The basal nociceptive threshold in REM sleep deprived rats was slightly, 
but significantly, lower tha~ in animals allowed undisturbed sleep (Fig 2, 
p<0.05). Deprenyl (5 mg/kg. i.p .. 60 min prior) induced a slight increase in 
the pain threshold of REMSD animals. A similar effect was observed during 
the first 10 min after PEA (40 ~g. i.c.v.) administration (data not shown). 
However, the analgesic scores of REM sleep deprived rats treated with 
deprenyl (5 mg/kg, i.p., Fig 2) or PEA (40 Mg. i.c.v., not shown) were not 
different from those of control animals (rats allowed undisturbed sleep). 
Phosphoramidon (250 Mg, i.c.v.) had no analgesic action in animals subjected 
to REMSD (Fig 2). The analgesic score of REM sleep deprived rats after 
administration of deprenyl (5 mg/kg, i.p., 60 min prior) and/or PEA (40 Mg, 
i.c.v., 5 min post-phosphoramidon) plus phosphoramidon (250 Mg, i.c.v.), was 
not different from those treated with deprenyl alone (Fig 2, p >0.05). 
DISCUSSION 
In the animals allowed undisturbed sleep, the antinociceptive effect of 
the enkephalinase inihibitor phosphoramidon was potentiated by both PEA 
(specific substrate for MAO-B) and 
enyzme). The analgesic effect 
deprenyl (selective inhibitor of this 
of phosphoramidon was probably due to an 
increase in endogenous enkephalins and the consequent activation of opioid 
receptors sensitive to naloxone and naltrexone (Chaillet et al., 1983; 
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Figure 2: The effects of deprenyl (D£P), REM sleep deprivation (REMSD) and 
e-phenylethylamine (PEA) on the analgesic effect of the enkephalinase 
inhibitor phosphoramidon (PH). Nociception was determined by withdrawal of 
hind paw from pressure stimulation (modified Randall-Selitto test). The 
analgesic score was measured 60 min after DEP and 15 min after PH or saline 
(2;.d icv,SAL). Each bar is the mean analgesic score ± SEM. The number of 
rats per group is indicated in parenthesis. Note the following: a) D£P (5 
mg/kg,ip) and/or PEA (40 ~g. icv) significantly potentiated the analgesic 
effect of PH in animals allowed undisturbed sleep; b) R£MSD decreased the 
basal pain threshold and Ph-induced analgesia compared to rats allowed 
undisturbed sleep; c) D£P and/or P£A did not alter the blockade of PH-induced 
analgesia by R£MSD. Tho levels of significance are given in the text. 
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Rupreht et al., 1983). We suggest that excess of PEA facilitates the 
analgesic action of enkephalins at the synaptic sites. This is in accordance 
with reports indicating that MAO-B inhibition and/or excess PEA potentiate 
the pharmacological effects of exogenously administered opiates /opioid 
peptides (Fuentes et al.; 1977, Garzon et al., 1980; 
1983). 
Ukporunwan et al., 
The mechanism by which MAO-B inhibition or excess PEA potentiates the 
analgesic effect of endogenously released enkephalins is not clear. It is 
possible that PEA enhances the interaction between opiates and their 
receptors (Fuentes et al., 1977). Thus. the MAO-B system may be an important 
regulator of the activity of opioids at the synaptic site in animal~ allowed 
undisturbed sleep. 
The described facilitatory action of MAO-B inhibition on enkephalinergic 
transmission in animals allowed undisturbed sleep might be of relevance not 
only in the physiology of nociception, but also in human disorders in which 
the alterations in MAO-B have been reported. For example, it has been 
demonstrated that endogenous depression is associated with a decrease in 
brain PEA levels (Wolf and Mosnaim, 1983), whereas an increase in MAO-B 
activity is associated with the aging process (Benedetti and Keane, 1980). 
In such cases an alteration in MAO-B activity and PEA levels could modify the 
analgesic effects of endogenous opioid peptides. 
However, the results of this study indicate that the possible alterations 
in the bioavailability of the MAO-B substrate, PEA, may not play an essential 
role in the failure of phosphoramidon to induce analgesia in REM sleep 
deprived rats. This statement is based on the fact that deprenyl and/or PEA 
did not alter the inhibitory effect of REMSD on phosphoramidon-induced 
analgesia. 
The basal pain threshold was lowered in rats deprived of REM sleep. TCis 
is in accordance with a previous study in which, using noxious electric shock 
to assess pain sensitivity, it was established that REMSD decreased the pain 
threshold (Hicks et al., 1979). The reason for the reduction in the pain 
threshold in REM sleep deprived rats is not clear. It might be due to the 
already suggested functional insufficiency of enkephalinergic/endorphinergic 
system during REMSD (Ukponmwan and Dzoljic, 1984b; Ukponmwan et al., 1985) 
since opioid peptides play an important role in the regulation of the pain 
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threshold (Basbaum and Fields. 1984). 
A functional insufficiency of an opioid system during REMSD (Ukponmwan et 
al., 1985) might partly explain why REM sleep curtailment is beneficial in 
treating some forms of depression (Vogel et al., 1980), since an increased 
opioid activity and corresponding decrease in pain sensitivity have been 
observed in this affective disorder (Risch, 1982; Pickar et al., 1982; 
Davis et al., 1979). 
Further clinical experiments are necessary to clarify the roles of MAO-B 
and the enkephalinergic/endorphinergic systems in the regulation of the pain 
threshold in human diseases. 
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CHAPTER 7 
REM SLEEP DEPRIVATION ANTAGONIZED THE MORPHINE-INDUCED AKINESIA AND CATALEPSY 
ABSTRACT 
An examination was made o£ the effect of REM sleep deprivation (REMSD) on 
some forms of altered motor activity, such as akinesia and catalepsy, induced 
by intraperitoneal (i.p.) or intracerebroventricular (i.c.v.) administration 
of morphine in adult, male Wistar rats . Administration of morphine (25 
mgjkg i.p.) induced an akinetic-cataleptic syndrome and decreased spontaneous 
vertical motor activity {SVMA) in animals allowed undisturbed sleep. REMSD 
decreased the morphine-induced akinesia and catalepsy that are known to be 
mediated by an inhibitory ~-opioid system. The locomotor depressant action 
of morphine was converted to excitation (manifested as increased SVMA and 
hopping behaviour) by REMSD. Similarly, decreased motor activity following 
i.c.v. administration of morphine (25 ~g) was replaced by excitation in the 
form of jumping behaviour after REMSD. Naltrexone (1 mg/kg,i.p.) blocked the 
akinetic and cataleptic effects, but not the excitatory effects of morphine. 
It is suggested that REMSD is associated with a functional insufficiency 
of an inhibitory ~-opioid system, thus unmasking the excitatory morphine 
effects. The proposed insufficiency of an endogenous opioid system might 
explain an increase in neuronal excitation during REMSD and the therapeutic 
effect of REM deficiency in some types of depression. 
INTRODUCTION 
Interactions between sleep and endogenous opioid systems have been 
documented. For example, activation of opioid receptor(s) .suppresses REM 
sleep (1 ). REM sleep was associated with the episodic release of humoral 
endorphin (2) and can decrease the neuronal excitation induced by exogenously 
administered opioid peptides (3). 
It has been suggested that alteration in REM sleep and endogenous opioid 
system are involved in some psychosomatic disturbances; for example, 
109 
increased REM sleep density and opioid activity are associated with 
endogenous depression (4-7). In addition, it has been shown that 
pharmacological and mechanical REM sleep deprivation can improve some ~arms 
of depression (8) and affect an opiate/opioid-induced analgesia (9). 
These data taken together suggest a functional interaction between REM sleep 
and opioid system in both physiological and pathological conditions. 
To further clarify the role of REM sleep in the regulation of opioid 
activity, the effects of REM sleep deprivation (REMSD) on morphine- induced 
behaviours were studied. Particular attention was paid to some 
morphine-induced effects such as akinesia and catalepsy, which are frequently 
present in psychopathological conditions (10). 
METHODS 
Adult, male Wistar rats weighing 1 50-200 
housed in groups of 3-5 rats per cage 
g 
(40 
were used. Animals were 
X 20 x 15 em) in constant 
environment chamber with a light-dark cycle 14:10 h (light phase, 07.00-21.00 
h) and ambient room temperature 22±1°C. 
REMSD 
Animals were deprived of REM sleep continously for 96 h using the 
classical -flower pot- technique previously 
procedure, rats were placed on platforms (14±0.5 
described ( 11). In 
cm2 /100 g body weight 
this 
to 
avoid the problem of unequal REMSD (12). The platform was surrounded by 
water 0.5-1.0 em below the island surface. This procedure is known to 
selectively deprive rats of REM sleep (11 ). In our experiment, the roof of 
the REMSD tank was designed to permit free assess to food and clean drinking 
water. The water in the tank was changed once every 24 h, during which time 
the animals were subjected to 1-2 min of handling and then allowed to rest in 
r.ome cages for 45-60 min and kept awake manually. 
Stress control 
To control for the unspecific stress factors associated with -flower pot-
technique for REMSD, rats were placed on platforms large enough (57-59 
cm2 /100 g body weight ) for them to curl up and have normal sleep without 
falling into the water. The large platform is known to stimulate the 
unspecific stress factors (isolation and dampness) associated with the 
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Nflower pot- technique of REMSD without affecting REM sleep after 96 h 
(11 ,1)). Otherwise, the stressed group of animals were treated as in REMSD 
group. 
Control 
Animals in this group were housed in home cages (40x20x15 em) for 96 h. 
Like the REMSD and stressed groups, rats in the control groups were handled 
daily for 1-2 mins. All animals had free assess to drinking water and food. 
Behavioural observations 
Behavioural observation and scoring were carried out in a quiet room with 
a temperature 22±2°C. Changes in behaviours were monitored in a transparent 
cylinder 18 em in diameter and 27 em height. The floor was covered with saw 
dust. REM sleep-deprived rats and stressed animals were placed in the 
recording cage within 5-10 min after discontinuation of these procedures. 
REM sleep deprived or stressed animals were first dried using absorbent 
towel, since they were often wet on removal from platforms. All rats were 
observed individually after 30 min habituation to the cage. Morphine-
induced behaviours such as akinesia. catalepsy, or rearing were assessed and 
scored as present or absent every 10 min for the first 30 min and every 30 
min thereafter for another 90 min. 
Akinetic and cataleptic behaviours 
Akinesia was defined as loss of spontaneous locomotor activity. A rat 
was scored as akinetic if it did not move for 5 min after placement at the 
corner of the cage. 
Catalepsy was determined using the bridge test and/or loss of righting 
reflex (14,15). In this procedure rats were placed gently across a 10 em 
wide bridge and/or on their backs. Animals that maintained this position for 
at least min were scored as cataleptic. All cataleptic animals were 
akinetic, but not all akinetic rats displayed catalepsy simultaneously; both 
phenomena were seperately evaluated. Hopping behaviour was defined as the 
sudden jump along a horizontal plane. 
~easurement of spontaneous vertical motor activity (SVMA) using an automated 
method 
During preliminary experiments, it was observed that REMSD converted 
morphine-induced locomotor inhibition into excitation, characterised by 
increased rearing. This effect of REMSD was particularly evident 60-120 min 
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after morphine treatment. Therefore the SVMA was assessed quantitatively in 
both REMSD and control groups. SVMA was recorded by means of a computerized 
Varimex (Columbus Instrument, Columbus, Ohio, USA), in which rearing animals 
interrupted a magnetic field located between the floor of the cage and a 
plane 18 em above. 
On the experimental day, rats were transferred from home cages or 
platforms, weighed, and placed in transparent Plexiglas cages (40 x 20 x 15 
em) without sawdust and allowed 30 min habituation. All animals were then 
injected with saline (1 ml/kg,i.p. ), and motor activity was recorded for an 
additional 30 min. Then, morphine (25 mg/kg, i.p.) was administered, and 
SVMA was monitored during the 60-120 min period after drug administration. 
The effects of morphine on SVMA vere studied between 11.00-14.00 h to avoid 
known circadian variation in locomotion (16) and opioid receptor reactivity 
(17). 
Drug, dose and route of administration 
Morphine hydrochloride (Brocacef, Maar sen, The Netherlands) was 
administered dissolved in physiological saline. The cataleptogenic and 
locomotor inhibitory effects of morphine vere studied at a fixed dose of 25 
mg/kg, i.p., since it has been shown that 20 mg/kg i.p. induce robust 
catalepsy/ridigity in rats (18). 
The intracerebroventricular (i.c.v.) administration of morphine (25 
~g/rat) was carried out by means of chronically implanted cannulae. This 
dose vas selected because it is known to induce the inhibitory effects of 
opiates (19). 
Statistical analysis 
Results expressed as percentages were analyzed using a one-tailed Fisher 
exact probability test. Data presented as counts were analyzed using the 
Kruskal Wallis one way analysis of variance (ANOVA) followed by a 
Mann-Whitney test. Statistical significance vas accepted at P-values of 0.05 
or less. 
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RESULTS 
Intraperitoneal (i.p.) administration of morphine 
Effect of REMSD on morphine-induced akinesia. Morphine(25 mg/kg) induced a 
significant akinetic behaviour in animal~ allowed undisturbed sleep (control 
and stress, Fig. 1, p<0.01 ). This akinetic effect of morphine in control 
and stressed animals reached maximum intensity within first 30-60 min and 
disappeared at 120 min after drug administration. However, there was no 
significant difference in the akinetic effect of morphine between control and 
stressed animals. 
REMSD significantly decreased morphine-induced akinesia compared with the 
control group at 30 min and 60 min (Fig. 1, p<0.05, p<0.005, respectively, 
for each time period). Furthermore, REMSD converted the akinetic e££ect to 
excitation characterised by rearing, body jerks, and hopping behaviours. 
Saline (1 ml/kg,i.p.) did not induce akinesia in control, stressed or REMSD 
animals. 
Effect of REMSD on morphine-induced catalepsy. The administration of morphine 
(25 mg/kg) induced signi£icant catalepsy in animals allo~ed undisturbed sleep 
(control and stressed rats) 30 and 60 min after drug treatment (Fig. 2, 
p<0.05). The morphine-induced catalepsy ~as characterised by a profound 
state o£ muscular ridigity (evident in the bridge test) and loss of righting 
re£lex, ~hich disappeared at 120 min. The number of rats sho~ing 
morphine-induced catalepsy in the control group ~as not significantly 
di££erent from stressed groups. A close relationship ~as observed bet~een 
akinesia and catalepsy, i.e. a signi£icant catalepsy score ~as registered in 
the control group only ~hen almost all animals sho~ed akinesia. 
Naltrexone (1 mg/kg, i.p.) completely blocked the morphine-induced 
akinetic-cataleptic syndrome in animals allo~ed undisturbed sleep (n~10 for 
control and stress groups together). 
REMSD signi£icantly decreased morphine-induced 
control animals allo~ed spontaneous amounts o£ 
p<0.005 for 30 and 60 min, respectively). 
catalepsy compared ~ith 
sleep (Fig. 2, p<0.02, 
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Effect of REMSD on morphine-induced inhibition of SVMA. Kruskal Wallis ANOVA 
showed a significant difference across the treatment groups (Fig. 3, 
p<0.001, H=20.39, df=5). 
Morphine (25 mg/kg) decreased SVMA in control animals. However, the 
morphine-induced inhibition of SVMA in stressed rats was not different from 
that in control animals (Fig. 3). In the REMSD group, morphine had the 
opposite effect. which was manifested as a significant increase in SVMA (Fig. 
3, p<0.02). This morphine-induc-ed increase in SVMA in the REM sleep deprived 
group was not altered by pretreatment with naltrexone (1 mg/kg,i.p., not 
shown). 
Intracerebroventricular administration of morphine. In animals allowed 
undisturbed sleep i.c.v. administration of morphine (25 ~g) induced 
decreased locomotion (with associated symptoms such as akinesia and 
catalepsy). However, the administration of morphine (25 ~g) to animals 
deprived of REM sleep provoked exctitatory behaviours such as hopping and 
jumping. The intensity of jumping behaviour in the REMSD group (25±9.5 
jumps/2h, n~7) was significantly higher than in control (no jumps in 2 h, 
n=5) and stressed animals (1.2±0.8 jumps/2h, n=5, p<0.01 ). 
DISCUSSION 
The results of this study indicate that the akinetic-cataleptic syndrome 
and locomotor suppressant effects of morphine were antagonised by REMSD and 
replaced by excitatory behaviours manifested as increased SVMA: hopping and 
jumping. 
It has been suggested that inhibitory effects of morphine such as 
akinesia and catalepsy are due to the activation of a naloxone/naltrexone 
sensitive ~-opioid receptor (20-22). This idea could be supported by this 
study, since a relatively low dose of ~ receptor blocking substance 
naltrexone decreased the morphine-induced akinetic-cataleptic syndrome. 
Therefore, a decrease of morphine-induced akinetic-cataleptic syndrome by 
REMSD might sugge~t an insufficiency of an endogenous opioid system mediating 
the inhibitory effects of opiates. Similarly, REMSD antagonised the 
analgesic effects of opiates (9), which is supposed to be mediated by the 
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same type of receptors (23,24). 
Although morphine fails to induce akinetic/cataleptic syndrome in REMSD 
animals. changes in other transmitter/modulators are probably not involved. 
For example, the observed decrease in brain concentrations of acetylcholine, 
Y-aminobutyric acid (GABA), and somatostatin during REMSD (25-27) cannot 
account for the inhibition of morphine-stimulated akinesia and catalepsy in 
REM sleep deprived animals, since blockade of cholinergic and GABAergic 
systems or the administration of somatostatin did not alter opiate-induced 
akinetic-cataleptic syndrome (28,29). Similarly, increased serotonin release 
facilitated akinesia and catalepsy (30), while an elevated brain turnover of 
serotonin was observed during REMSD (31). A number of studies indicate a 
functional hyperactivity of dopaminergic system following REMSD (32). It is 
known that clinically effective neuroleptics that act as antagonists at 
dopamine receptors may induce catalepsy (33). However, opiates do not act as 
antagonists of dopamine receptors (34). 
A second important finding was that REMSD converted the depressant 
effects of intracerebroventricularly administered morphine to excitation. 
The reason for the conversion of the depressant effects of morphine to 
excitation by REMSD is not clear. However, morphine can induce both 
inhibitory and excitatory behaviours. which are mediated by two groups of 
receptors. 
mediates 
One is the naloxone-sensitive opioid receptor system which 
analgesia, akinesia and catalepsy: the other is the 
naloxone-insensitive receptor system which mediates excitation (21 ,35,36). 
Activation or blockade of the ~~opioid receptor can inhibit and facilitate, 
respectively, the excitatory effect of morphine (36). Thus. the conversion 
of the motor inhibitory effects of morphine to excitation during REMSD could 
be explained by the suggested deficiency of an inhibitory ~-opioid system in 
REM sleep deprived animals and a corresponding predominance of the excitatory 
opioid receptor system. 
Therefore, in conclusion, we suggest that functional insufficiency of ·a 
~-opioid system during REMSD might be a background to increased neuronal 
excitability in REM sleep deprived animals. Namely, it is known that 
endogenous opioids exert an inhibitory influence on the release of excitatory 
transmitters (37). This possiblity can be supported by the report that 
blockade of opioid receptors with naloxone facilitated epileptogenesis (38). 
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The proposed insufficiency of an opioid system during REMSD might be an 
explanation for a therapeutic and diagnostic value of REM sleep curtailmen~ 
in some cases of depression (8) and epilepsy (39), respectively. 
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CHAPTER 8 
REM SLEEP DEPRIVATION DECREASES THE GROOMING AND SHAKING BEHAVIOUR INDUCED BY 
ENKEPHALINASE INHIBITOR OR OPIATE WITHDRAWAL 
ABSTRACT 
Intraventricular administration of enkephalinase inhibitor, 
phosphoramidon (1 X 10-S- 5.6 x 10-7 moles, i.c.v.) induced a behavioural 
syndrome consisting of excessive grooming with body scratching as the most 
prominent symptom and wet-dog-shakes (WDS). The frequency of the 
phosphoramidon-induced WDS and bo~ scratching were decreased by the 
pretreatment with the opioid receptor blocking agent, naltrexone (2.9 x 10-6 
moles/kg, i.p.). Both the phosphoramidon-induced WDS in naive rats and 
naloxone-precipitated withdrawal WDS were decreased in REM sleep deprived 
rats compared with animals allowed normal sleep (control and stress groups). 
The results are discussed in light of a possible functional insufficiency 
of an endogenous opioid system during REMSD. It has been suggested that this 
insufficiency might be a background to the increased neuronal excitability 
during REMSD. 
INTRODUCTION 
Several endogenous substances including opioid peptides have been 
demonstrated to induce grooming and wet-dog-shakes (5,6.9,12). Recently, we 
demonstrated that the administration of the enekphalinase inhibitor, 
phosphoramidon, induced behaviours such as grooming and wet-dog -shakes (WDS) 
{28). These behavioural phenomena. which can be induced by various drugs in 
naive animals, are part ol the morphine withdrawal syndrome. There are 
indications that both groom~ng and WDS may share a common neural mechanism 
( 1 0) . 
It has been demonstrated that inhibition ol protein synthesis reduced the 
severity of opiate withdrawal phenomena (19). In addition it is known that 
REM sleep deprivation (REMSD) can decrease protein synthesis (30). REMSD 
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also inhibited morphine induced analgesia (38). These data suggest that 
alterations in REM sleep can modulate both protein synthesis 
pharmacological effects of opiate substances. Therefore, we analyzed the 
relationship between REMSD and grooming and/or shaking behaviour induced by 
enkephalinase inhibitor phosphoramidon in naive rats 
naloxone-precipitated withdrawal in the opiate-dependent rats. 
METHODS 
Adult, male Wistar rats (100-125 g) housed in transparent plastic cages 
in a constant environment room with a light-dark cycle 14:10 (light phase 
07.00 -21.00 h) were used. 
Intracerebroventricular (i.c.v.) administration of drug solutions 
For i.c.v. administration of drugs a stainless steel guide cannula was 
stereotaxically directed mm above the lateral ventricle. Drug solutions 
(maximum volume 2 ~1) were injected into the lateral ventricle with guage 30 
needle, attached to a Hamilton microsyringe by polyethylene (PE) tubing. The 
length of the needle was made such that it protruded 1 mm into the lateral 
ventricle. The injection was made over 10 sec and the needle maintained in 
position for an additional 10 sec. Correct ventricular cannulation was 
verified before and after each experiment using a modification of the 
technique previously described by Paakkari (24). In this procedure a PE 
tubing is attached to the injection needle and filled with artificial 
cerebrospinal fluid (CSF) or saline. To test the correct placement of i.c.v. 
cannula during sugery, the tubing is raised above the head of the animal on 
the stereotaxic apparatus, and a rapid inflow of saline denotes a correct 
placement of cannula. The cannula was moved only in a downward direction to 
avoid the possible false positive effect due to an upward movement of the 
cannula after the first unsuccessful cannulation (14). 
REM sle&p deprivation (REMSD) 
REMSD was carried out according to the conventional -flower pot-
technique previously described (21). In this procedure, rats were placed on 
platforms (14 cm2/100 g rat) surrounded by water, such that the water level 
was 0.5-1.0 em below the platform. Rats made morphine-dependent were placed 
on platform and deprived of REM sleep from day 7-11 (96 hr) of 
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morphinization. During this period animals received the normal doses of 
morphine for these days. 
Forty-five to 60 min after the discontinuation of REMSD the animals were 
injected with the enkephalinase inhibitor phosphoramidon. In this period of 
time the animals were kept awake mannually. 
scored during the following 30 min. 
The behavioural changes were 
Control for the unspecific stress factors associated with the -flower pot-
technique 
In order to control for the known stress factors (dampness, isolation and 
immobilisation) associated with the -flower pot- technique rats were placed 
on platforms large enough (60 cm2 /100 g rat) for them to curl up and have 
normal sleep. The large platform can simulate the chronic stress condition 
associated with REMSD without affecting REM sleep level after 96 hr (20,21). 
Phosphoramidon-induced behaviour 
Behavioural observation and scoring were carried out on each individual 
rat housed singly in Plexiglas cages (40 x 20 x 15 em) containing saw dust . 
Wet-dog-shakes consisting of paraxysmal shudder of the whole body along the 
spinal axis were registered and quantified. The body scratching (BS) episode 
is defined as head or body scratches followed immediately by the licking of 
the paw used in scratching. 
Induction of morphine dependence 
Animals were made dependent on morphine according to the repeated 
injection procedure previously described (32). In this method rats were 
given two intraperitoneal injections of morphine daily (at 07.30 and 15.30 
hr). The dosage schedule was as follows: Days and 2 (7 X 10-5 
moles/kg/day; Days 3 and 4 ( 14 X , o- 5 moles/kg/day); Days 5 and 6 (28 X 
10-5 moles/kg/day) and Days 7-11 (56 X 10-5 moles/kg/day). 
Precipitation of morphine withdrawal shaking behaviour 
Abstinential behaviour in morphine dependent animals was provoked by 
injecting nalxone (3.1 x 10-6 moles/kg i.p.) three hours after the last 
injection of morphine. Prior to receiving naloxone treatment each rat was 
allowed a habituation period of 30-60 min in the observation area. 
Naloxone-precipitated WDS in morphine-dependent rats and phosphoramidon-
induced behavioural phenomena in naive animals were studied in the following 
three groups of rats:- a) Control group:- these rats were housed singly in 
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home cages throughout the experimental procedure and allowed spontaneous 
amounts o~ sleep; b) REM sleep deprived group:- these rats were submitted to 
96 hr continous REM sleep deprivation; c) stressed group:- these animals 
were chronically stressed for 96 hr. 
Drugs 
The following drugs were used: morphine hydrochloride (Merck). naloxone 
hydrochloride (Endo Lab) and naltrexone hydrochloride (Endo Lab) were 
administered dissolved in physiological saline. Phosphoramidon (Peninsula 
Lab) was dissolved in CSF prepared fresh and administered i.c.v. 
Data Analysis 
The results were analyzed using the Kruskal-Wallis one-way ANOVA. The 
statistical difference between two groups of treatment were carried out using 
a two-tailed Mann Whitney U test. except vhen indicated in text. 
RESULTS 
Effects of REMSD on behavioural syndrome induced by enkephalinase inhibiton 
The intracerebroventricular administration of the enkephalinase inhibitor 
phosphoramidon (1 x 10-8 - 5.6 x 10-7 moles i.c.v.) induced a behavioural 
syndrome consisting of excessive grooming (as measured by body scratching) 
and vet-dog -shakes (WDS) in all three groups of animals (control, REMSD and 
stressed). These symptoms appeared vithin 5 min after phosphoramdion 
administration and vere still observed after 240 min. The Kruskal-Wallis one 
vay ANOVA shoved a significant difference in the phosphoramdion-induced WDS 
across the groups (H=1 06.21, NDF:8 p<0.001). The frequency of 
phosphoramidon-induced WDS vas dose-related in both control (p<0.05) and 
stressed (p<0.02) groups of animals (Fig 1 ). Hovever, the frequency of the 
phosphoramidon-induced WDS in stressed rats was not significantly different 
from control animals (Fig 1. p>0.05). REMSD significantly decreased the WDS 
induced by three doses of phosphoramidon (Fig 1, p<0.02, p<0.002, p<0.002 
respectively, for increasing doses). The frequency of BS in the REM sleep 
deprived animals vas significantly less intensive compared with control and 
stressed animals (Fig 3, p<0.02). There vas no significant difference in the 
mean BS between control and stressed animals (Fig 3, p>0.10). 
Naltrexone (2.9 x 10-6 moles/kg i.p .• 10 min prior) significantly 
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Figure 1: The phosphoramidon (1 x 10-B- 5.5 x 10-7 moles i.c.v.)- induced 
wet-dog-shakes (WDS). Each point is mean ± S.E.M. The number of rats per 
dose of phosphoramidon is stated in parentheses. Note that the 
phosphoramidon-induced WDS was significantly lowered in REMSD rats compared 
with control or stressed animals. 
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decreased the phosphoramdion-induced ~S in control (p<0.002), REMSD and 
stressed animals (p<0.05, Ducan Ne~ Multiple range test)(Fig 2). In the 
control rats the phosphoramidon-induced BS were signi~icantly less frequent 
after pretreatment with naltrexone (92.8±23.6. n=11) compared with saline 
pretreated animals 201 .8±29, n=12, p<0.05). 
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Figure 3: Effect oF REMSD on phosphoramidon (5.6 x 10-7 moles, i.c.v.) 
induced body scratches. Each bar is mean± S.E.M. The number of rats per 
treatment group is stated in parentheses. Note that the intense body 
scotches induced by phosphoramidon in control and stressed animals were 
significantly decreased by REMSD. 
Effect of REMSD on opiate withdrawal WDS 
Naloxone (3.1 x 10-6 mole/kg i.p.) precipitated WDS in morphine-dependent 
rats in control. REM sleep deprived and stressed groups of animals. The 
Kruskal-Wallis one way ANOVA showed a significant difference in the 
withdrawal WDS across the groups (Fig 4, H=16.12, NDF=2. p<0.001 ). The 
frequency of the precipitated WDS was significantly more pronounced in 
128 
8 
{ n =1 0) 
7 
-
c 
= 0 6 {n=1 0) 
M 
~ 
w 
"' rn 
.c 5 -
Vl 
' Ol 
0 
0 
.:. 
" 4 
"' 
'" • rn 
" "0 
.c 3 {n =13) 
"' 1 ~ 0 
" w 
.0 2 
= ~ 
z 
0 
CONTROL REMSD STRESS 
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-precipitated withdrawal wet-dog-shakes (WDS). Each bar is mean ± S.E.M. 
The number oT rots per group is indicated in parentheses. Note that the 
total frequency of withdrawal WDS was significantly less in REMSD rats 
compared with control (p<0.01) and stressed (p<0.002) animals. 
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animals allowed to sleep normally (control and stressed groups) than in the 
REM sleep deprived rats (Fig 4, p<0.002). However, the intensity of such 
induced WDS in control or stressed animals were not significantly different 
(Fig 4, p>0.2). 
were few 
Body scratchings in naloxone-treated morphine dependent rats 
irregular and therefore omitted from further detailed 
quantitative evaluation. 
DISCUSSION 
The results of this study showed that WDS and grooming induced by 
enkephalinase inhibitor, phosphoramidon, were inhibited by naltrexone, which 
might indicate an involvement of opioid receptor(s). This is consistent with 
the fact that enkephalinase inhibition can activate opioid receptors by 
blocking the 
(16,25). 
biotransformation 
In addition, the 
of endogenously 
WDS-induced by 
released opioid peptides 
i.c.v. administration of 
enkephalins were attenuated by opiate antagonists (2,5,6,13) 
Grooming behaviour has also been observed after low doses of morphine 
(29). Taken together, these data might suggest that WDS and grooming induced 
by phosphoramidon or opioid substances share a common mechanism. 
The biological significance of WDS and grooming induced by different 
chemical compounds is not clear. Some data suggest that WDS are indicative 
of arousal (10), whereas grooming might be a -de-arousing- homeostatic 
mechanism (17). In addition, it has been demonstrated that opioid peptides 
facilitate arousal (37) and in higher doses induced an electrophysiological 
and behavioural phenomena similar to epilepsy (7,8). Thus the excessive 
grooming observed in our experiment might be a response to the 
phosphoramidon-induced arousal, manifested as WDS. 
However, the most important aspect of this report is the fact that REMSD 
suppressed the WDS and grooming induced by enkephalinase inhibition in naive 
rats. Why REMSD decreased these behaviours in rats is not clear. It could, 
however, be suggested that REM sleep deprived animals might have limited 
availability of opioid peptides and hence the WDS and grooming precipitated 
by phosphoramidon could be less pronounced. Although there is no direct 
biochemical evidence for the insufficiency of the enkephalinergic system 
during REMSD this possibility could be considered since it is known that 
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REMSD is associated with the inhibition of protein synthesis (30). The 
concept of a functional insufficiency in the enkephalinergic/endorphinergic 
system in REM sleep deprived animals receives further support from the fact 
that REMSD abolished the antinociceptive effects of morphine and 
phosphoramidon (38). 
This hypothesis of a functional insufficiency in this opioid system might 
explain the increased neuronal excitability during REMSD (4) since it is 
known that oPioid peptides exhibit tonic inhibitory effects on the release of 
excitatory transmitters (23). However, additional experiments are required 
to clarify whether this mechanism might be involved in REMSD-precipitated 
seizures and the therapeutic effect of REMSD in some types of endogenous 
depression. 
A second important finding of this study is that REMSD inhibited 
abstinential WDS. The mechanism of opiate addiction/withdrawal is complex 
and probably involves alteration in several neurotransmitter/neuromodulator 
systems. However, the known changes in classical transmitters during REMSD 
can not account for the decrease in naloxone-precipitated withdrawal WDS in 
REM sleep deprived animals. For example, REMSD increased the functional 
activity of dopaminergic system (36), but did not alter the adrenergic system 
(31 ). However, substances which block these systems inhibited withdrawal WDS 
(18,34) Furthermore, the known changes in brain serotonin metabolism during 
REMSD (33} probably play no role in the inhibiton of abstinential WDS in REM 
sleep deprived rats, since the alteration of the serotoninergic system had no 
clear effect on WDS induced by morphine withdrawal (1 ). It is also known 
that drugs which stimulate central muscarinic receptors inhibited the shaking 
response (39), whereas REMSD decrease the acetylcholine content of the brain 
(3.35). 
Although some high energy phosphates can antagonize the effects of 
morphine, there is no evidence that the concentrations of AMP, ADP and ATP 
are significantly altered by REMSD (11 ,22). 
Therefore, an alternative explanation for the inhibitory effect of REMSD 
on morphine withdrawal WDS should be considered. Namely, it is known that 
during development of morphine dependence there is an increase of the 
synthesis of secretory proteins in the brain regions (pons-medulla and 
stratum -septum)(27), which are particularly rich in opioid receptors (26) 
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and functionally involved in opiate dependence (15). It has also been 
demonstrated that REMSD decreased protein synthesis in the cerebral and brain 
stem fractions (30) and that synthesis can decrease opiate withdrawal 
phenomena (19). Thus the decrease of protein synthesis during REMSD might 
explain the inhibitory effect of REMSD on withdrawal WDS. 
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CHAPTER 9 
ENKEPHALINASE INHIBITION ANTAGONIZES THE INCREASED SUSCEPTIBILITY TO SEIZURE 
INDUCED BY REM SLEEP DEPRIVATION 
ABSTRACT 
In order to elucidate the relationship between REM sleep and the 
enkephalinergic system, the effects of REM sleep deprivation (REMSD), stress 
and the enkephalinase inhibitor phosphoramidon on 
handling-induced-convulsions were studied in mice. REMSD, stress and 
phosphoramidon (25-500 ~g i.c.v.) increased the frequency of handling-induced 
convulsions (HIC) in normal mice. However, only in the last two groups were 
RIC antagonized by naloxone (1 mg/kg i.p.). In REMSD mice, phosphoramidon 
decreased the frequency of HIC, this effect being abolished by naloxone. The 
increase of neuronal excitability during REMSD is suggested to be associated 
with an insufficiency of an enkephalinergic system. 
INTRODUCTION 
Rapid-eye-movement (REM) sleep is known to modulate neuronal excitability 
in man and animals (Drucker-Colin et al., 1977; Passouant et al., 1965). 
However, in clinical reports and animal experiments, it has been demonstrated 
that REM sleep deprivation (REMSD) increases 
facilitates seizure activity (Pratt et al .• 1969; 
neuronal excitability and 
Cohen and Dement, 1965). 
Evidently. the phasic changes in neuronal activities during sleep can 
influence the pathophysiology of seizures. 
Recently, it has been suggested that the enkephalinergic system plays an 
important role in epileptogenesis (Frenk et al .• 1978; Dzoljic et al., 
1979). It is also known that ~-endorphin exerts an inhibitory influence on 
REM sleep (King et al., 1981 ). In addition, we have demonstrated that REM 
sleep has an inhibitory effect on enkephalin-induced seizures (Ukponmwan and 
Dzoljic, 1983). These data might indicate an involvement of the endogenous 
opioid system in mechanisms regulating REM sleep and neuronal excitability. 
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In order to eludicate further the relationship between REM sleep and 
enkephalins, we studied the effects of REMSD, stress and the enkephalinase 
inhibitor, phosphoramidon on handling-induced convulsions in mice. 
MATERIALS AND METHODS 
Animals: 
Adult, male mice of B10 A strain (25-30 g) were used (Dlac Ltd, Bicester, 
England). Intracerebroventricular (i.c.v.) administration of drugs was by 
means of a stainless steel cannula stereotaxically implanted in the lateral 
ventricle. A minimum of 3-5 days was allowed for recovery before experiments 
were commenced. 
Animals were then divided into three groups: Group A (control) mice 
housed individually in transparent cages and allowed spontaneous amount of 
sleep; Group B mice were subjected to 72 h REMSD according to the 
conventional -flower pot- technique described by Fishbein {1970). Only mice 
which could habituate to the platform within 3 h were used for 
experimentation. Group C (stress) mice were placed on platforms large enough 
(8.0 em diameter, for 72 h) for the animals to curl up and exhibit REM sleep 
without falling into the water. 
Handling-induced convulsions (HIC): 
HICs in mice were assessed using the criteria previously described for 
alcohol withdrawal (Goldstein and Pal, 1971 ). In this procedure each mouse 
was picked up 
characterised 
by 
by 
the tail 
violent 
and/or 
jerking 
spun gently through 180°. HIC was 
or twirling, tonic convulsions 
tightening of facial muscle (grimace). Only HICs occuring within 6-10 s of 
pick-up were recorded. Scores were assigned as follows: violent 
tonic-clonic convulsions upon pick up-4, tonic-clonic convulsions upon 
picking up-3, tonic convulsions upon picking up or tonic-clonic convulsions 
after gently spinning-2, tonic convulsions after gentle spinning-1. and 
facial grimace after gentle spinning-0.5. The scoring procedure is based 
upon the criteria described by Crabbe et al. (1981 ). RIC was determined at 
10 min intervals form 120 min. The intensity of convulsions is indexed by 
total HIC during the first 30 min scoring period. The period was chosen to 
avoid the possible modifying influence of repeated handling. The observer 
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was -blind- during the evaluation of dose-response curve of the effect of 
phosphoramidon in all three groups. 
Drugs: 
Phosphoramidon (Peninsula Laboratories) and naloxone hydrochloride 
(Winthrop Laboratories) were dissolved in saline. The maximum volume of 
phosphoramidon administered i.c.v. over 20 s was 1 .5~1. 
administered intraperitoneally (i.p.). 
Statistical analysis oF data: 
Naloxone was 
The Kruskal-Wallis ANOVA was carried out on the mean convulsions score 
and across all data in all the experiments. Comparisons between any two 
treatment groups were made with the Mann-Whitney U-test (Siegel, 1956). 
RESULTS 
The Kruskal-Wallis test showed significant differences in convulsion 
scores across the groups (H=174.47, p<0.001, NDF=15). The levels of 
significance between two groups using the Mann-Whitney U test are indicated 
below. 
Control. In this study, 16% of control non-treated mice displayed mild signs 
of HIC such as grimacing. In treated mice, saline injection (1~1 i.c.v.) or 
naloxone also induced signs of HIC consisting mainly of grimacing. However, 
phosphoramidon (25-500 ~g i.c.v.) significantly increased the intensity and 
degree of susceptibility to HIC in a dose-related manner (p<0.01 ). This 
effect was antagonized by naloxone (1 mg/kg. i.p.)(Fig 1A). 
R£MSD group. Mice subjected to 72 h REMSD demonstrated a significant 
increase in the incidence and intensity of HIC (p<0.001 ). This was not 
affected by naloxone (p=o.1) but significantly inhibited by the enkephalinase 
inhibitor phosphoramidon (25-500 ~g) administered within 10 min after REMSD 
termination (p<0.001, Fig 1B). This effect of phosphoramidon was partially 
antagonised by naloxone (1 mg/kg i.p. 10 min prior, p<0.001 ). 
Stress group. Stress also induced an increase in the intensity and 
susceptibility to RIC (p<0.001) but less intensely than in REMSD group. This 
effect was further potentiated by phosphoramidon (100 ~g. p<0.001 ). Naloxone 
(1 mg/kg, i.p.) decreased the susceptibility to HIC in stress animals 
(p<0.001 Fig 1C). 
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Figure 1a-c: The erTect of REM sleep deprivation (REI'ISD, 72 h). 
phosphoramidon (ph), naloxone (nal) and stress (72 h) on handling-induced-
convulsions (HIC). Each bar is mean intensity± S.E.M of HIC during the 
first 30 min. The number of animals per group is stated in parentheses. 
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DISCUSSION 
Mice subjected to REMSD, stress or 
increase in the susceptibility to 
phosphor amidon 
HIC. HoYever, 
treatment showed an 
only in stressed or 
phosphoramidon-treated animals was the convulsant activity antagonised by 
naloxone. This might indicate that the phosphoramidon- and stress-induced 
proconvulsant activity is due to activation o£ an endogenous opioid system. 
This agrees with data -showing that concentrations of opioid peptides are 
increased after treatment with enkephalinase inhibitors (Patey et al., 1981) 
and that various stress regimens are associated with the release of 
endogenous opioid peptides (Christie and Chesher, 1982). The evidence that 
stress and enkephalinase inhibition increase susceptibility to epileptiform 
activity could be ascribed to the fact that opioid peptides in excess may 
induce seizure phenomena. The epileptogenic potential of various opioid 
peptides administered exogenously has been demonstrated frequently (Urea et 
al., 1977; Dzoljic et al., 1979; Snead and Bearden, 1982). 
However, the mechanism of epileptiform activity of opioid peptides is not 
completely understood. Recent data suggest that specific opioid receptors of 
the delta-subtype mediate the epileptiform effect of these substances 
(Dzoljic and vd Poel-Heisterkamp, 1982; Haffmans and Dzoljic, 1983; Frenk, 
1983). The target area of this action seems to be the limbic system 
(Henriksen et al., 1980), particularly the hippocampus (French and Siggins, 
1980; Haffmans et al., 1983; 1984). It has been shown that opioid peptides 
may excite hippocampal neurons by inhibiting adjacent interneurons 
(Zieglgansberger et al., 1979). Thus, it might be suggested that an 
increased susceptibility to HIC in animals, stressed or treated with 
phosphoramidon is due to the a~tivation of a particular type of opioid 
receptor population in selective brain regions(s). The potentiating effect 
of phosphoramidon on stress-induced HIC is probably due to the protection of 
the released opioid peptides during the stress procedure. 
A second significant aspect of this study is that the enkephalinase 
inhibitor phosphoramidon decreased convulsant behaviour in REMSD mice. This 
effect of enkephalinase inhibition might suggest that REMSD is associated 
with an insufficiency of endogenous opioid peptides. This possibility is 
supported by the fact that REMSD decreases peptide synthesis (Shapiro and 
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Girdwood, 1981) and affects the levels of some brain peptides (Mattiace et 
al., 1981 ). In addition, recent data indicate that nocturnal episodic 
secretion of humural endorphins occurs during REM sleep (Oksenberg et al., 
1980). 
However, the exact mechanism by which an enkephalinase inhibitor 
antagonizes REMSD-induced neuronal excitation is not clear. One possible 
explanation that should be considered is the fact that enkephalins block GABA 
transport across plasma membrane (Cupello and Hyden, 1981 ), leaving GABA 
outside the neuronal membrane in contact with its receptors for a longer 
time. Such mechanism might explain enkephalin-induced neuronal inhibition in 
physiological circumstances. In the context of these findings, a proposed 
decrease o£ enkephalinergic ac~ivi~y during REMSD would be associated with a 
decrease GABA inhibitory activity and consquent increase 
susceptibil ty. 
in seizure 
In summary, these results indicate that enkephalinase inhibition may 
have, depending on conditions. proconvulsant potential (in stress or control 
animals) or anticonvulsant (in REMSD animals) action. Similar contradictory 
data concerning the proconvulsant potential o£ morphine and endogenous 
opioids have been reported. Both the pro- and anticonvulsant activity o£ 
these substances have been demonstrated (Gilbert and Martin, 1975; Verdeaux 
and Marty, 1954: Cowan et al., 1979; Tortella et al., 1981; Dzoljic, 
1982). 
An insu£~iciency of endogenous opioid peptides in REMSD animals suggested 
by this study might be of importance £or the worsening o£ seizures or 
improvement o£ depressive disorders during REMSD (Pratt et al., 1968; Vogel 
et al., 1980). It is of interes~ to note that in nacolepsy, the attacks of 
REM sleep have been prevented by naloxone, suggesting a possible involvement 
o£ endogenous opioid systems (Pasi et al., 1983). 
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CHAPTER 10 
REM SLEEP DEPRIVATION INHIBIT THE NITROUS OXIDE WITHDRAWAL CONVULSIONS 
ABSTRACT 
The e£fect of REM sleep deprivation (REMSD) ~as investigated using 
withdrawal convulsions in mice following exposure to nitrous oxide (N2 D). 
REMSD for 72 h significantly decreased the severity of withdrawal convulsions 
following acute exposure to N20. 
The results were interpreted in the light of protein synthesis inhibition 
during REMSD. REMSD procedure might stimulate a new approach to the 
treatment of withdrawal neuronal excitability. 
INTRODUCTION 
It is known that REM sleep deprivation (REMSD) results in a decrease in 
protein synthesis (Drucker-Galin and Rojas-Ramirez, 1976) and is often 
associated with an increase in neuronal excitability. For example, the 
threshold ~or electroconvulsive shocks (Cohen and Dement, 1965) and 
amygdaloid kindling (Calvo et al., 1982) is greatly reduced following REMSD. 
Patients recovering from nitrous oxide anaesthesia are known to exhibit 
an increase in excitability (Eckenhoff et al., 1961 ). Similarly, mice 
exposed to nitrous oxide showed convulsions when picked up by the tail after 
removal from the anaesthetic (Harper et al., 1980). This seizure pattern is 
known to occur after exposure to nitrous oxide, ethylene and cyclopropane and 
it is considered to be a type of withdrawal convulsions (Smith et al., 1979). 
It is of interest to note that some types of epileptic attacks are 
associated with REM sleep dysfunction (Passouant, 1976) and also with drug 
addicition (Herzlinger et al .• 1977; Mendelson and Mello, 1978). 
In this study we report on the inhibitory effect of REMSD on nitrous 
oxide withdrawal convulsions. 
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METHODS 
Adult, male mice o£ the B10A strain weighing 32±0.2 g at the onset of 
experiment were used. Throughout the investigation the animals were housed 
under constant light/dark cycle (light phase 09.00-21 .00). The room 
temperature was maintained at 24±°C. Food and water were available ad 
libitum. The number of animals used in each procedure is stated in the 
results. 
REMSD was carried out according to the conventional water tank method 
previously described (Fishbein et al., 1971 ). This method selectively 
deprives mice of REM sleep and with slight effect on slow wave sleep. In 
this study, each mouse was placed on a platform (3 em diameter, 1 em above 
the water le~el) surrounded by water (3 em deep). The water was replaced at 
least once in 24 h. Only mice which could adjust to this experimental 
condition within 2 h were used in experiments. 
Stress control group for REMSD consisted of mice placed on platform (6 em 
in diameter ) under the same experimental conditions as in REMSD. A second 
stress consisted of mice forced to swim in water 3 em deep at 18°C for two, 1 
h sessions daily. These two stress control procedures produced comparable 
weight loss as in REMSD (10-15%). 
Nitrous oxide withdrawal convulsion was induced and assessed according to 
the method of Goldstein and Pal (1971 ). In this procedure mice were exposed 
to a mixture of nitrous oxide and oxygen (80:20) at 1.6 atm for h. Each 
mouse was picked up by the tail and spun gently through 180°. Mice showing 
violent jerking or twirling and/or grimace were quantified as positive. Mice 
were tested for the presence or absence of handling-induced convulsions (HIC) 
every 10 min after the removal from N20, until there were no convulsions in 
two successive tests. Throughout this study, all testing of HIG was carried 
out between 10.00-14.00 h to avoid circadian alterations in 
threshold. 
seizure 
Statistical analysis:The number of animals convulsing after N2D withdrawal ~n 
control, stressed and REMSD groups were compared using the Kx2 method (de 
Jong, 1963). Statistical signifcance was accepted at P-values of 0.05 or 
less. 
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RESULTS 
Nitrous oxide withdrawal convulsions (n~2D) 
Mice exposed to N20 showed withdrawal convulsions lasting about 2 h with 
highest incidence within 20 min after removal from N2o. The mice convulsed 
when picked up by the tail following 
convuslions (HIC) consisted of 
N2 0 anaesthesia. 
violent jerking 
These handling-induced 
and twirling (clonic 
components) and arching of the back and contractions of head muscle 
(-grimace-, tonic components). 
REM sleep deprivation (n=20) 
Mice subjected to REMSD for 24-120 h showed increased susceptibility to 
HIC. However. mice subjected to REMSD for 72 h showed a decrease in the 
degree of susceptibility to N20 withdrawal convulsions (Fig A1 ). Stress did 
not inhibit N2o withdrawal convuslions (n=10), but instead exacerbated it. 
Combined REMSD and an enkephalinase inhibitor phosphoramidon (Hudgin et al., 
1981) also decreased the frequency of HIC but not to a degree significantly 
different from REMSD or phosphoramidon given alone (Fig A.1 ). 
DISCUSSION 
Mice exposed to N2 o develop very quickly a drug dependence which is 
characterized by withdrawal convulsions. This is demonstrated when mice are 
picked up by the tail following N20 anaesthesia. This type of convulsions 
was conteracted by REM sleep deprivation (REMSD), in spite of the fact that 
REMSD could induce neuronal excitation in the normal animals. 
The neurobiological basis of acute N2 o tolerance withdrawal 
convulsions is still unclear, it is does not appear to involve changes in 
synaptic membrane fatty acid, phospholipid and cholesterol (Koblin et al., 
1979). However the possible involvement of endogenous opioid peptides in N2 o 
tolerance and withdrawal excitation has been demonstrated. Acute exposure to 
N2 o induced an increase in the cerebrospinal fluid met-enkephalin levels 
(Qock et al., 1985), whereas the administration of morphine or naloxone can 
inhibit and facilitate, respectively, the N2o withdrawal convulsions (Manson 
et al., 1983). This suggests that N2 o stimulates an opioid-like dependence. 
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Figure A.1: The effect of R£~ sleep deprivation (REMSD) on nitrous oxide 
withdrawal convulsions. Control consists of mice not subjected to any 
treatment. (*)denotes statistical significance at p < 0.05 level compared 
to control or stress. Note that 1) REMSD significantly reduced the frequency 
and duration of nitrous oxide withdrawal convulsions; 2) phosphoramidon did 
not alter the inhibitory action of REMSD on nitrous oxide withdrawal 
convuslions. The effect of the enkephalinase inhibitor phosphramidon was not 
considered in this chapter. 
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It is known that several drugs with the common ability to inhibit protein 
synthesis reduced the development of dependence to opiates (Feinberg and 
Cochin, 1 972; Bowman and Rand, 1980) and decrease REM sleep (Drucker-Colin 
and Rojas-Ramirez, 1976). In addition REMSD has also been reported to 
decrease protein synthesis in some nuclei of the rat brain stem (Bobillier et 
al., 1974; Panov, 1982). The antagonistic effect of REMSD on N2 D withdrawal 
convulsions, might be due to decrease in protein synthesis, which in turn 
blocked the development of tolerance and physical dependence. 
Stressed animals showed enhanced susceptibility to N2o withdra"W"al 
convulsions proving that the inhibitory action of REMSD on N20 withdrawal 
convulsions is not related to the unspecific effects (dampness, isolation and 
restriction) of the experimental procedure. 
Apart from the uncertainty of the interactions between REMSD and N2o 
withdrawal syndrome, the results of this study indicate that REMSD might 
prove useful as new approach to the management of withdrawal neuronal 
hyperexcitability. 
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CONCLUDING REMARKS AND S1JMMARY 
In chapter a general review of the literature on sleep-waking 
mechanisms, functions of sleep, and the biological and therapeutical effects 
of sleep deprivation was provided. Chapter 2 gave a brief review of the role 
of the endogenous opioid system in physiological regulation. 
In this thesis the role of endogenous opioid peptides in the regulation 
of sleep-waking states and the effects of REM sleep on reactivity to 
endogenously released and exogenously administered opioid peptides. or 
opiates, are reported. We explored the possibility that REM sleep is 
involved in regulating the functioning of opioid peptidergic neurons in the 
central nervous system by studying the effects of REM sleep deprivation 
(REMSD) on behavioural responses to endogenously released opioid peptides and 
exogenously administered opiates and opioid peptides. The following 
opioid/opiate-induced behavioural responses were examined in this thesis 
analgesia, akinesia-catalepsy, spontaneous vertical motor activity (SVMA), 
convulsions, grooming and nitrous oxide and morphine withdrawal symptoms. 
Endogenous opioid peptides and waking mechanism (s) 
The possible involvement of endogenously released opioid peptides in 
waking mechanism (s) is suggested by the diurnal oscillations in enkephalin 
and ~-endorphin concentrations in brain nuclei, involved in vigilance state 
regulation (chapter 1, sections 1.2, 1.3.2i). Thus, concentrations of 
~-endorphin, enkephalins and dynorphin in the rat brain are highest in the 
dark, during which wakefulness is high, and lowest in the light phase, when 
propensity to sleep is at its highest. 
In our study we demonstrated that the inhibition of enkephalinase, with 
phosphoramidon, induced an increase in wakefulness. Both NREM and REM sleep 
stages were suppressed. The increased wakefulness induced by enkephalinase 
inhibition was accompanied by excitatory symptoms, such as head shakes, 
scratching (chapter 3) and excessive grooming, which normally precede sleep 
in rats (chapters 2, section 1 .3.2i and 8). The insomnic action of 
phosphoramidon was decreased by naltrexone. These data suggest that opioid 
receptors and endogenous enkephalins play an important role in sleep-waking 
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mechanism (chapter 3). This idea might be o~ relevance in some clinical 
situations. For example, an increase in opioid peptide levels has been 
demonstrated during stress, anxiety and psychic disturbances associated with 
insomnia. It is also conceivable that this new class of drugs, the 
enkephalinase inhibitors, might be of potential use in the treatment of sleep 
disorders characterised by excessive somnolence. 
Sleep-waking states and enkephalin induced neuronal excitation 
The intracerebroventricular (icv) administration of enkephalin was found 
to induce epileptiform activity in the hippocampal and cortical EEG and in 
the EMG derived from submandibular muscle in freely moving rats (chapters 4). 
Sleep, in particular REM sleep, decreased the enkephalin-induced epileptiform 
discharges. 
These observations indicate that phasic changes during sleep-waking 
states can modulate the neuronal excitability regulated by opioid peptides. 
This might be of importance for some forms of human epilepsies affected by 
the sleep-waking cycle. 
RE~ sleep deprivation and nociception 
REMSD decreased the pain threshold and abolished the analgesic effects of 
morphine. enkephalinase inhibition and cold-water-swim (CWS) (chapters 5 and 
6). The pain threshold to noxious electric shock was similarly reduced by 
REMSD (chapter 1, section 1 .5.2d, vii). All these data suggest that REM 
sleep is an important factor in the physiological regulation of 
The finding that REMSD can reduce the pain threshold 
nociception. 
might be of 
relevance for those individuals who suffer from disturbed sleep e.g. 
insomnia or people working in shifts. In general it should be expected that 
pathological conditions. and/or drug treatment accompanied with REMSD, could 
modify the therapeutic effectiveness of opiates and other analgesic 
procedures. 
REM sleep deprivation and monoamine-opioid interactions 
There are abundant data showing that opioid peptides interact with many 
other physiologically active substances. In our study we paid particular 
attention to ~-phenylethylamine (PEA), a substrate for the MAO-B enzyme, 
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since it is known that inhibition of MAO-B modulates some effects of opioid 
peptides (chapter 6, introduction). In our study, the inhibition of MAO-B 
(the enzyme which biodegradates PEA) and excess of PEA (a substrate for 
MAO-B) had a stimulatory effect on the analgesic action of endogenously 
released opioid peptides in rats allowed undisturbed sleep, but not in REMSD 
animals (chapter 6). 
The described facilitatory action of MAO-B inhibition on enkephalinergic 
transmission might be of relevance not only in the physiology of nociception, 
but also in conditions associated with the alterations of MAO-B enzyme and/or 
REM sleep (endogenous depression, ageing etc). 
REM sleep deprivation induces a Functional deFiciency oT ~ opioid receptor 
system 
The finding that opiate-induced analgesia, which is due to a preferential 
activation of ~-opioid receptors, can be blocked by REMSD suggested a 
functional insufficiency of a ~-receptor system (chapters 5, 6). In order to 
test this concept. we studied the effects of REMSD on opiate induced motor 
inhibition. In this study we demonstrated that the morphine induced 
akinesia/catalepsy syndrome, which is characterised by rigidity and mediated 
mainly by the ~-opioid receptors. was abolished by REMSD and replaced by 
motor excitation, seen as an increase in spontaneous vertical motor activity 
(SVMA). Naltrexone blocked the morphine induced akinesia/catalepsy in rats 
allowed undisturbed sleep, but not the opiate induced increase in SVMA in 
REMSD animals (chapter 7). In addition to the fact that REMSD blocked 
opioid/opiate-induced analgesia akinetic-cataleptic syndrome, the 
naltrexone sensitive wet-dog-shakes and grooming behaviours stimulated by an 
enkephalinase inhibitor were attenuated in REMSD animals (chapter 8). 
These data collectively indicate that the blockade of akinesia/catalepsy 
syndrome and the reduced effects of enkephalinase inhibition in REMSD animals 
are due to a functional insufficiency of the ~-opioid receptor system, 
allowing for an increased expression of the naltrexone resistant excitatory 
opioid receptors responsible for the increased SVMA. It is known for example 
that blockade of 
morphine (chapter 
~-opioid receptors facilitates the excitatory effects of 
7, discussion). The idea that REMSD can induce a 
functional deficit of an opioid system derives further support from the fact 
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that enkephalinase inhibition blocked the proconvulsant action o~ REMSD 
(chapter 9). This proposition can be supported by the known inhibitory 
influence of opioid peptides on the release of excitatory transmitters and 
that blockade of ~-opioid receptors vith naloxone facilitates epileptogenesis 
(chapter 7. discussion). The suggested functional deficiency of an opioid 
system might explain the increase in neuronal excitability in REMSD animals. 
Some recent biochemical studies. provide evidence for the concept of 
derangement of endogenous opioid system during REMSD. For example REMSD 
decreased the concentrations of ~-endorphin in the pituitary but increased it 
in the hypothalamus (chapter 1, section 1 .5.2b, vi). We have also observed 
that REMSD reduced the concentrations o~ leu-enkephalin in some brain areas 
(Haf~mans, Ukponmwan, Dzoljic in preparation). 
The proposed insuf~iciency o~ an opioid system during REMSD could account 
~or the therapeutic and diagnostic value o~ REM sleep curtailment in some 
cases o~ depression and epilepsy respectively (chapter 7, discussion). 
REM sleep deprivation and opiate dependence 
Acute expose to nitrous oxide can lead to the release o~ met-enkephalin 
in the CSF and opiate-like dependence phenomena (chapter 2, section 2.5.2, 
iv). The withdrawal convulsions in mice following exposure to nitrous oxide 
were reduced by REMSD (chapter 10). Similarly, naloxone-precipitated 
wet-dog-shakes in morphine-dependent rats were attenuated by REMSD (chapter 
8). It has also been demonstrated that REMSD attenuate 
naloxone-precipitated jumping and myoclonic contractions in acute morphine 
dependent rats (Dzoljic et al. in preparation). Although the neurochemical 
basis of drug dependence is not fully understood, it has been established 
that several drugs which can inhibit protein synthesis reduced the severity 
o~ opiate dependence and withdrawal phenomena (chapter 2, section 2.4.8). 
REMSD has also been demonstrated to decrease protein synthesis in the rat 
brain (chapter 1, section 1 .5.2b, vii). It is therefore suggested that the 
antagonistic e~~ect of REMSD on opiate or nitrous oxide withdrawal phenomena 
might be due to a decrease in protein synthesis in animals deprived of REM 
sleep. 
The ~inding that REMSD can attenuate abstinential symptoms might suggest 
the existence of a common link between REM sleep de~iciency and drug 
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dependence. However, the mechanism by which REMSD inhibits abstinential 
syndromes and whether it modulates drug dependence in humans remain to be 
clarified. 
The following general conclusions can be made from this thesis:-
7o) Activation of endogenous opioid peptides increased wakeFulness 
1b) Sleep, particularly the REM sleep stage, decreased the epileptic effects of 
enkephalin when compared with the waking state. Statements 1a and 1b 
indicate that there is an interaction between vigilance and the endogenous 
opioid system. 
2) Inhibition of monoamine oxidase B and/or excess of ~-phenylethylamine 
facilitated enkephalinergic transmission in rats allowed undisturbed sleep 
but not in RE~SD animals. This finding might be of relevance in some 
clinical situations associated with the alterations of MAO-B and/or REM 
sleep (endogenous depression, ageing, etc). 
3) Stimulation of the endogenous opioid system, with enkephalinase inhibition, 
attenuated the proconvulsant action of REMSD, suggesting an involvement of 
opioid peptides in the regulation of neuronal excitability. 
4) The analgesic effects of endogenously released enkephalins and exogenously 
administered opiates, which are mediated mainly by #-opioid receptor, were 
abolished by REMSD. This suggests that normal REM sleep is an important 
factor for proper regulation of the pain threshold. 
5) The akinetic/cataleptic effect of morphine, also mediated by #-opioid 
receptors, was replaced by excitatory motor activity in REMSD rats. 
6) Conclusions 4 and 5 suggest that REM sleep deprivation may be associated 
with a functional insufficiency of #-opioid system. 
7) REM sleep deprivation decreased abstinential phenomena, suggesting that 
sleep deprivation could be an attractive tool in the investigation of drug 
dependence. 
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SAMENVATTING EN CONCLUSIES 
In het eerste hoofdstuk werd een algemeen literatuuroverzicht gegeven over 
slaap-waak mechanismen, de functies van slaap en de biologische en 
therapeutische effecten van slaapdeprivatie. In hoofdstuk 2 werden de 
fysiologische regulaties 
systeem in de vorm van 
hierin 
een 
toegespitst op de rol van het endogene opioid 
korte samenvatting van de literatuur. Dit 
proefschrift beschrijft een onderzoek naar de rol van endogene opioid peptiden 
in de regulatie van slaap-waak stadia en de invloed van REM slaap op de effecten 
van endogeen gesecreteerde- en exogeen toegediende opioid peptiden en opiaten. 
Met name is de mogelijke betrokkenheid van de REM slaap bij de functionele 
regulatie van opioid peptiderge neuronen in het centrale zenuwstelsel van de rat 
onderzocht, via het bestuderen van de e~~ecten van REM slaap deprivatie (REMSD) 
bij bepaalde ge~ragsresponsies op endogeen gesecreteerde opioid peptiden en 
exogeen toegediende opiaten en opioid peptiden. In dit onderzoek werden de 
volgende door opiaat/opioid geinduceerde gedragsresponsies bestudeerd: 
analgesie, akinesie-catalepsie, spontane verticale motorische activiteit (SVMA), 
convulsies, poetsgedrag en opiaat onthoudingssymptomen opgewekt door lachgas en 
morfine. 
Endogene opioid peptiden en waak mechanisme(n) 
De mogelijke betrokkenheid van endogene opioid peptiden bij waak 
mechanisme(n) zou afgeleid kunnen worden uit de dag~luctuaties in enkefaline en 
E-endorfine concentraties in bepaalde hersenkernen die een rol spelen bij 
alertheidsregulering (hoofdstuk 1, sectie 1 .2, 1 .3.2i). Dienovereenkomstig zijn 
de concentraties van E-endorfine, de enkefalines en dynorfine in rattehersenen 
het hoogste in de nacht of in het danker, wanneer de waakzaamheid hoog is, en 
zijn ze het laagst gedurende de dag of in het licht, wanneer de neiging tot 
slapen het grootst is. De remming van het enzym enkefalinase door toediening 
van het farmacon fosforamidon bleek een verhoging van de waakzaamheid te 
induceren. Zowel de NREM als de REM slaap periodes werden onderdrukt. Deze 
toegenomen waakzaamheid als gevolg van de remming van enkefalinase werd 
vergezeld door symptomen van geprikkeldheid zeals schokbewegingen van de kop, 
krabben (hoofdstuk 3) en overmatig poetsgedrag, dat normaal bij ratten aan het 
slapen vooraf gaat (hoofdstuk 2, sectie 1 .3.21 en hoofdstuk 8). Het bleek dat 
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de opwekkende Werking van fosforamidon werd verminderd door de opiaat antagonist 
naltrexon. Deze gegevens suggereren dat opioid receptoren en endogene 
enkefalines een belangrijke rol spelen in het slaap-waak mechanisme (hoofdstuk 
3). Dit mogelijke verband zou in bepaalde situaties klinische implicaties 
kunnen hebben. 
concentraties 
Er is bij voorbeeld bij de mens een toename in 
aangetoond gedurende stress. angsttoestanden 
endogene opioid 
storingen die samengaan met slapeloosheid. Het is ook 
en 
voorstelbaar 
psychische 
dat een 
nieuw type van farmaca, de enkefalinase remmers, potentieel van nut zou kunnen 
zijn bij de behandeling van patienten die lijden aan excessieve slaperigheid. 
Slaap-waak stadia en inductie van neuronal& excitatie door enkefaline 
De intracerebroventriculaire (i.c.v.) toediening van enke~aline induceerde 
epilepti~orme activiteit in de hippocampus en de cortex volgens het EEG en was 
ook zichtbaar aan het EMG van de submandibulaire spieren bij vrij bewegende 
ratten (hoofdstuk 4). Slaap, en in het bijzonder de REM slaap, kon de door 
enkefaline geinduceerde epilepti~orme ontladingen doen verminderen. 
Deze observaties geven aan dat fasische verschuivingen in slaap-waak stadia 
het ef~ect van opioid peptiden op de neuronale prikkelbaarheid, kunnen 
moduleren. Dit zou bij de mens betekenis kunnen hebben voor bepaalde vormen van 
epilepsie, waarop de slaap-waak cyclus een invloed heeft. 
REM slaap deprivoti& en pijnprikkeling 
REMSD verminderde de pijndrempel en antagoniseerde het analgetische e~~ect 
resp. mor~ine, enkefalinase remming, en in-koud-water-zwemmen 
(CWS)(hoofdstukken 5 en 6). 
De pijndrempel veer een electrische schok kan eveneens verminderd worden door 
REMSD (hoofdstuk 1, sectie 1.5.2d.vii). Al deze gegevens duiden erop dat REM 
slaap een belangrijke ~actor is in de ~ysiologische regulatie van 
pijnprikkeling. 
De waarneming dat REMSD de pijndrempel kan verlagen, zou betekenis kunnen 
hebben voor die personen die aan een gestoorde slaap lijden zeals bijvoorbeeld 
slapeloosheid bij mensen die in ploegendienst werken. In het algemeen zou men 
kunnen verwachten dat pathologische omstandigheden en/o~ een bepaalde 
behandeling met farmaca die vergezeld gaan met REMSD, de therapeutische 
effektiviteit opiaten en andere analgetische behandelingen kunnen 
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beinvloeden. 
REM sloop deprivatie en monoamine-opioid interakties 
Er is een veelheid aan in~ormatie in de literatuur die laat zien dat de 
effecten van opioid peptiden interfereren met die van vele andere fysiologisch 
actieve stoffen. In dit proefschrift is in dit verband bijzondere aandacht 
besteed aan t-fenylethylamine (PEA), een substraat voor het MAO-B enzym, omdat 
bekend is dat remming van MAO-B bepaalde effecten van opioid peptiden kan 
beinvloeden (hoofdstuk 6: -introduction-). Remming van MAO-B (het enzym dat 
PEA afbreekt) en een overmaat aan PEA (het substraat voor MAO-B) hadden een 
stimulerend effect op de pijnstillende ~erking van endogeen gesecreteerde opioid 
peptiden bij ratten die ongestoord konden slapen, maar niet bij ratten waarbij 
de REM slaap werd onthouden (REMSD)(hoofdstuk 6). 
Het effect van MAO-B remming op enkefalinerge transmissie, die zoals 
beschreven neurotransmissie bevorderend is, kan niet alleen van betekenis zijn 
voor het begrip van de fysiologie van pijnprikkeling bij de mens, maar oak voor 
die van bepaalde pathologische condities die verband houden met veranderingen in 
de activiteit van het MAO-B enzym of van de hoeveelheid REM slaap zoals bij 
endogene depressies of bij het verouderen. 
REM slaap deprivatie en de inductie van een funktionele deficientie in het 
~-opioid receptor system 
De bevinding dat de analgesie die door een opiaat wordt geinduceerd en die 
het gevolg is van een stimulering van voornamelijk de ~-type opioid receptoren. 
geblokkeerd kan worden door REMSD, werd geinterpreteerd als een functionele 
insufficientie in het ~-type receptor systeem (hoofdstukken 5 en 6). Om deze 
opvatting te kunnen toetsen, is vervolgens het effect van REMSD op de door 
opiaten veroorzaakte motorische activiteitsvermindering bestudeerd. Uit deze 
studie kwam naar voren dat het door morfine geinduceerde akinesiejkatalepsie 
syndroom, dat gekarakteriseerd wordt door een lichaamsstarheid als gevolg van 
een preferentiele ~-receptor stimulering, werd tegengegaan door REMSD en zelfs 
werd vervangen door motorische activiteitsvermeerdering in de vorm van een 
toegenomen spontane vertikale motorische activiteit (SVMA). De opioid receptor 
antagonist naltrexon blokkeerde de door morfine geinduceerde akinesiejkatalepsie 
in ratten die ongestoord konden slapen, maar niet de door morfine geinduceerde 
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toename in SVMA in dieren met REMSD (hoofdstuk 7). Naast de hierboven 
beschreven waarnemingen dat REMSD de door opioiden en opiaten geinduceerde 
analgesie en het akinesie/katalepsie syndroom kan blokkeren, bleek dat in dieren 
met REMSD het opioid geinduceerde gedrag, zeals de naltrexon-sensitieve 
-wet-dog-shakes- en het door een enkefalinase remmer geinduceerde poetsgedrag, 
eveneens verzwakt werd (hoofdstuk 8). 
Uit het geheel van deze waarnemingen zou men kunnen concluderen dat de 
blokkering van het akinesie/katalepsie syndroom en de verminderde effecten van 
de enkefalinase remming in REMSD dieren worden veroorzaakt door een functionele 
insufficientie van het ~-opioid receptor systeem. De toegenomen SVMA wordt 
hierbij toegeschreven aan een zichtbaar geworden expressie (demaskering) van 
opwekkende opiaat-effecten, middels een ander 
receptor type. Het is bijvoorbeeld bekend 
en naltrexon-resistent opioid 
dat blokkering van ~-opioid 
receptoren de expressie van opwekkende effecten van morfine kan vergemakkelijken 
(hoofdstuk 7: discussie). Het denkbeeld dat REMSD een functioneel tekort in 
een opioid systeem kan induceren, wordt verder ondersteund door het feit dat 
remming van het enzym enkefalinase het proconvulsieve effect van REMSD kan 
blokkeren (hoofdstuk 9). Deze bewering wordt ondersteund door het bekende feit 
van de remmende werking van opioid peptiden op de afgifte van stimulerende 
neurotransmitters, waarbij een blokkering van ~-opioid receptoren met naloxon 
het ontstaan van epileptische verschijnselen vergemakkelijkt (hoofdstuk 7: 
discussie). Het veronderstelde functionele tekort in een opioid systeem zou 
aldus de toename in normale prikkelbaarheid in REMSD dieren kunnen verklaren. 
Enkele recente biochemische studies ondersteunen het concept van een 
verstoring van endogene opioid systemen als gevolg van deprivatie van REM slaap. 
REMSD verminderde bijvoorbeeld de concentratie van E-endorfine in de hypofyse. 
maar in de hypothalamus nam deze concentratie toe (hoofdstuk 1, sectie 1 .5.2b. 
vi). In overeenstemming hiermee vinden wij in bepaalde hersengebieden ook 
verminderde concentraties van leu-enkefaline als gevolg van REMSD (Haffmans, 
Ukponmwan, Dzoljic; in voorbereiding). 
De veronderstelde functionele insufficientie van een opioid systeem als 
gevolg REMSD zou verantwoordelijk kunnen zijn voor het gewenste 
therapeutische effect en de diagnostische waarde van het beperken van REM slaap 
bij respectivelijk bepaalde types depressie en epilepsie (hoofdstuk 7: 
discussie). 
159 
REM slaap deprivatie en lichamelijke afhankelijkheid van opiaten 
Een acute inhalatie van lachgas kan de afgifte van Met-enkefaline in de 
hersenvloeistof verhogen en aldus opiaat-achtige lichamelijke afhankelijkheids 
fenomenen oproepen. De convulsies als element van de onthoudingsverschijnselen 
bij muizen na lachgas inhalatie waren verminderd in REMSD dieren (hoofdstuk 10). 
Hiermee vergelijkbaar was het door naloxon opgeroepen -wet-dog-shakes- gedrag in 
ratten die tevoren morfine afhankelijk gemaakt waren, minder uitgesproken in 
REMSD dieren. Oak i~ aangetoond dat REMSD het door naloxon opgeroepen spring 
gedrag en de myoclonische contracties bij ratten die acuut morfine-afhankelijk 
gemaakt zijn, kan verzwakken (Dzoljic et al., 
neurochemische basis van afhankelijkheid van 
in voorbereiding). Hoewel de 
verdovende middelen en andere 
substanties niet bekend is, is wel vastgesteld dat verschillende stoffen die de 
eiwitsynthese remmen de mate van opiaat afhankelijheid en van 
onthoudingsverschijnselen doen verminderen (hoofdstuk 2. sectie 2.4.8). Het is 
aangetoond, dat REMSD de eiwitsynthese in ratte hersenen vermindert (hoofdstuk 
1. sectie 1 .5.2b, vii). Om deze reden wordt voorgesteld, dat het 
antagonistische effect van REMSD op opiaat en lachgas onthoudingsverschijnselen 
veroorzaakt zou kunnen worden door een afname van de eiwitsynthese bij dieren 
met REM slaap onthouding. 
De waarneming dat REMSD opiaat onthoudingsverschijnselen kan verzwakken, 
veronderstelt 
lichamelijke 
het bestaan 
afhankelijkheid 
onthoudingsverschijnselen kan 
lichamelijke afhankelijkheid 
onderzocht worden. 
een verband tussen REM slaap tekort en 
opiaten. Het mechanisme waardoor REMSD 
verzwakken en of REMSD invloed kan uitoefenen op 
van opiaten bij de mens meet echter nader 
Uit de resultaten van dit proefschrift kunnen de volgende algemene conclusies 
getrokken worden: 
1a) Activering van het endogene opioid systeem doet de waakzaamheid toenemen. 
1b) Slaap, in het bijzonder het REM slaap stadium, vermindert de epileptische 
effecten van enkefaline. vergeleken met het waak-stadium. De stellingen 1a 
en 1b geven aan dot er een interactie is tussen de mate van waakzaamheid en 
het endogene opioid systeem. 
2) Remming van monoamine oxidase 8 en/of een overmaat aan ~-fenylethylamine 
vergemakkelijkt enkefalinerge transmissie in rotten die ongestoord kunnen 
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slapen, maar niet in rotten met REM sloop deprivatie. Daze conclusie zou 
voor de mens betekenis kunnen hebben in bepaalde klinische situaties, 
waarin veranderingen in MA0-8 enzym activiteit en/of REM sloop een rol 
spelen (endogene depressie, veroudering, enz.). 
3) Stimulering van het endogene opioid systeem via ramming van het enzym 
enkefalinase verzwakt de proconvulsieve werking van REM$0, hetgeen een 
betrokkenheid van opioid peptiden in de regulatie van neuronale 
prikkelbaorheid gesuggereert. 
4) De analgetische werking van endogeen gesecreteerde enkefalines en van de 
exogeen toegediende opiaten, die voornamelijk het ~-opioid receptor type 
stimuleren, vordt tegengegaan door REMSD. Hieruit kan men concluderen dat 
een normale REM slaap een belangrijke Taktor is voor een adequate 
installing van de pijndrempel. 
5) Het akinetische/kataleptische effect van morfine, dat ook via de stimulatie 
van ~-opioid receptors werkt, wordt in REMSD rotten vervangen door een 
verhoogde motorische activiteit. 
6) Uit de conclusies 4 en 5 zou men kunnen afleiden dat REM slaap deprivatie 
geassocieerd is met een functionele insufficientie van het ~-opioid 
systeem. 
7) REM slaap deprivatie vermindert opiaat onthoudingsverschijnselen, hetgeen 
doet vermoeden dot slaap deprivatie een aantrekkelijk hulpmiddel zou kunnen 
zijn bij verslavingsonderzoek. 
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